<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="pmc">F1000Research</journal-id>
            <journal-title-group>
                <journal-title>F1000Research</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2046-1402</issn>
            <publisher>
                <publisher-name>F1000 Research Limited</publisher-name>
                <publisher-loc>London, UK</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.12688/f1000research.139228.1</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Research Article</subject>
                </subj-group>
                <subj-group>
                    <subject>Articles</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Co-rotating twin screw process for continuous manufacturing of solid crystal suspension: A promising strategy to enhance the solubility, permeation and oral bioavailability of Carvedilol</article-title>
                <fn-group content-type="pub-status">
                    <fn>
                        <p>[version 1; peer review: 1 approved with reservations]</p>
                    </fn>
                </fn-group>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Navti</surname>
                        <given-names>Prerana D.</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Software</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Fernandes</surname>
                        <given-names>Gasper</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Soman</surname>
                        <given-names>Soji</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Software</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Nikam</surname>
                        <given-names>Ajinkya N.</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-6268-6667</uri>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Kulkarni</surname>
                        <given-names>Sanjay</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Software</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Birangal</surname>
                        <given-names>Sumit R</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Software</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-7129-5748</uri>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Dhas</surname>
                        <given-names>Namdev</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Data Curation</role>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Shenoy</surname>
                        <given-names>Gautham G.</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Software</role>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Rao</surname>
                        <given-names>Vinay</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <xref ref-type="aff" rid="a3">3</xref>
                </contrib>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Koteshwara</surname>
                        <given-names>Kunnatur Balasundara</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Mutalik</surname>
                        <given-names>Srinivas</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Conceptualization</role>
                    <role content-type="http://credit.niso.org/">Project Administration</role>
                    <role content-type="http://credit.niso.org/">Resources</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Validation</role>
                    <role content-type="http://credit.niso.org/">Visualization</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-0642-1928</uri>
                    <xref ref-type="corresp" rid="c1">a</xref>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <aff id="a1">
                    <label>1</label>Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India</aff>
                <aff id="a2">
                    <label>2</label>Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India</aff>
                <aff id="a3">
                    <label>3</label>STEERLife, Steer Engineering Pvt Ltd, No. 290, 4th Main Road, Ganapathy Nagar, Phase 3, Peenya Industrial Area, Peenya, Bengalore, Karnataka, 560058, India</aff>
            </contrib-group>
            <author-notes>
                <corresp id="c1">
                    <label>a</label>
                    <email xlink:href="mailto:ss.mutalik@manipal.edu">ss.mutalik@manipal.edu</email>
                </corresp>
                <fn fn-type="conflict">
                    <p>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>6</day>
                <month>11</month>
                <year>2023</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2023</year>
            </pub-date>
            <volume>12</volume>
            <elocation-id>1438</elocation-id>
            <history>
                <date date-type="accepted">
                    <day>1</day>
                    <month>10</month>
                    <year>2023</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2023 Navti PD et al.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <self-uri content-type="pdf" xlink:href="https://f1000research.com/articles/12-1438/pdf"/>
            <abstract>
                <p>
                    <bold>Background:</bold> In the current work, co-rotating twin-screw processor (TSP) was utilized to formulate solid crystal suspension (SCS) of carvedilol (CAR) for enhancing its solubility, dissolution rate, permeation and bioavailability using mannitol as a hydrophilic carrier.</p>
                <p>
                    <bold>Methods:</bold> 
                    <italic toggle="yes">In-silico</italic> molecular dynamics (MD) studies were done to simulate the interaction of CAR with mannitol at different kneading zone temperatures (KZT). Based on these studies, the optimal CAR: mannitol ratios and the kneading zone temperatures for CAR solubility enhancement were assessed. The CAR-SCS was optimized utilizing Design-of-Experiments (DoE) methodology using the Box-Behnken design. Saturation solubility studies and 
                    <italic toggle="yes">in vitro</italic> dissolution studies were performed for all the formulations. Physicochemical characterization was performed using differential scanning calorimetry , Fourier transform infrared spectroscopy, X-ray diffraction studies, and Raman spectroscopy analysis. 
                    <italic toggle="yes">Ex vivo</italic> permeation studies and 
                    <italic toggle="yes">in vivo</italic> pharmacokinetic studies for the CAR-SCS were performed. Stability studies were performed for the DoE-optimized CAR-SCS at accelerated stability conditions at 40 &#x00ba;C/ 75% RH for three months.</p>
                <p>
                    <bold>Results:</bold> Experimentally, the formulation with CAR: mannitol ratio of 20:80, prepared using a KZT of 120 &#x00ba;C at 100 rpm screw speed showed the highest solubility enhancement accounting for 50-fold compared to the plain CAR. Physicochemical characterization confirmed the crystalline state of DoE-optimized CAR-SCS. 
                    <italic toggle="yes">In-vitro</italic> dissolution studies indicated a 6.03-fold and 3.40-fold enhancement in the dissolution rate of optimized CAR-SCS in pH 1.2 HCl solution and phosphate buffer pH 6.8, respectively, as compared to the pure CAR. The enhanced efficacy of the optimized CAR-SCS was indicated in the 
                    <italic toggle="yes">ex vivo</italic> and 
                    <italic toggle="yes">in vivo</italic> pharmacokinetic studies wherein the apparent permeability was enhanced 1.84-fold and bioavailability enhanced 1.50-folds compared to the plain CAR. The stability studies showed good stability concerning the drug content.</p>
                <p>
                    <bold>Conclusions:</bold> TSP technology could be utilized to enhance the solubility, bioavailability and permeation of poor soluble CAR by preparing the SCS.</p>
            </abstract>
            <kwd-group kwd-group-type="author">
                <kwd>Twin screw processor</kwd>
                <kwd>solid crystal suspension</kwd>
                <kwd>carvedilol</kwd>
                <kwd>mannitol</kwd>
                <kwd>solubility</kwd>
                <kwd>in vitro dissolution</kwd>
                <kwd>ex vivo permeation</kwd>
                <kwd>in vivo pharmacokinetics</kwd>
            </kwd-group>
            <funding-group>
                <funding-statement>The author(s) declared that no grants were involved in supporting this work.</funding-statement>
            </funding-group>
        </article-meta>
    </front>
    <body>
        <sec id="sec1" sec-type="intro">
            <title>Introduction</title>
            <p>The bioavailability of drugs 
                <italic toggle="yes">via</italic> the oral route majorly depends on the drug solubility and the dissolution rate. Solubility acts as a rate-determining step for the effective therapeutic response of the drug.
                <sup>
                    <xref ref-type="bibr" rid="ref1">1</xref>
                </sup> Specifically, the drugs belonging to the biopharmaceutical classification system (BCS) class II suffer from poor absorption and low bioavailability. Therefore, there is a concern about increasing the solubility of these drug candidates.
                <sup>
                    <xref ref-type="bibr" rid="ref2">2</xref>
                </sup> Many approaches like co-solvency, surfactants, micronization, complexation, hydrotropy, salt formation, cocrystals, and co-amorphous technology have been extensively utilized for the solubility enhancement.
                <sup>
                    <xref ref-type="bibr" rid="ref1">1</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>
                </sup>
            </p>
            <p>A new theory known as solid crystal suspensions (SCS) has recently been proposed wherein the ground drug is homogeneously distributed in the crystalline carrier matrix using hot-melt extrusion (HME) without aiding in any drug and the crystalline matrix interaction, forming a stable product having a better dissolution rate compared to the bulk drug.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup> Highly hydrophilic carriers enhance the drug solubility in the SCS. The enhanced wetting and drug particle size reduction improve the dissolution and solubility of the poorly soluble drug.
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup> This system differs from that of the amorphous solid dispersions,
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>
                </sup> which are thermodynamically unstable because of their ability to get converted to a more stable crystalline form. Also, moisture absorption for the amorphous forms is more severe than the crystalline state and results in agglomeration of the amorphous form. Since no amorphous phase is involved, the physical stability of SCS is higher.</p>
            <p>Carvedilol is an alpha and beta-blocker utilized in hypertension treatment belonging to BCS class II with high permeability and low solubility. The bioavailability of carvedilol is very low orally, which accounts for only 25%. Hence, there is an immense need to enhance its solubility and improve bioavailability.
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref7">7</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref8">8</xref>
                </sup> The approaches utilized for solubility and dissolution rate improvement of carvedilol include micronization,
                <sup>
                    <xref ref-type="bibr" rid="ref7">7</xref>
                </sup> solid dispersion,
                <sup>
                    <xref ref-type="bibr" rid="ref9">9</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref10">10</xref>
                </sup> cyclodextrin inclusion complex,
                <sup>
                    <xref ref-type="bibr" rid="ref11">11</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref12">12</xref>
                </sup> cocrystallization,
                <sup>
                    <xref ref-type="bibr" rid="ref3">3</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref13">13</xref>
                </sup> co-amorphous technology
                <sup>
                    <xref ref-type="bibr" rid="ref14">14</xref>
                </sup> and nanotechnology.
                <sup>
                    <xref ref-type="bibr" rid="ref8">8</xref>
                </sup> To date, the SCS approach has not been explored for solubility enhancement of carvedilol.</p>
            <p>HME technology has previously been reported for the preparing SCS of several drugs such as efavirenz,
                <sup>
                    <xref ref-type="bibr" rid="ref5">5</xref>
                </sup> griseofulvin,
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>
                </sup> and griseofulvin, phenytoin, and spironolactone.
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>
                </sup> However, the HME machines reported in earlier studies for SCS preparation consisted of a single barrel with only one heating zone in which temperature variation is quiet difficult.
                <sup>
                    <xref ref-type="bibr" rid="ref4">4</xref>
                </sup>
                <sup>&#x2013;</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref6">6</xref>
                </sup> There are no reports on the application of twin-screw processor (TSP) technology using different heating zones in the preparation of SCS. Twin screw processing refers to directing the raw materials in the machine consisting of one or two rotating screws wherein the starting materials are exposed to different temperatures, followed by passing the material via the die to give the product.
                <sup>
                    <xref ref-type="bibr" rid="ref15">15</xref>
                </sup>
                <sup>,</sup>
                <sup>
                    <xref ref-type="bibr" rid="ref16">16</xref>
                </sup> The fed material creates a melt pool inside the melting zone of the extruder facilitating the interaction and homogenous mixing between the raw materials.
                <sup>
                    <xref ref-type="bibr" rid="ref16">16</xref>
                </sup> This technology has been used for the solubility/dissolution enhancement of poorly soluble drugs by crystal engineering, cyclodextrin complexation and by cocrystal manufacture.
                <sup>
                    <xref ref-type="bibr" rid="ref16">16</xref>
                </sup> Different heating zones in the barrel allow heat distribution, heat optimization, and adaptation of the processing section for the product.
                <sup>
                    <xref ref-type="bibr" rid="ref17">17</xref>
                </sup> Because of this reason, altering the temperature in a barrel is essential. Typically, the temperature in the melting and kneading zone is greater compared to the conveying zone.
                <sup>
                    <xref ref-type="bibr" rid="ref17">17</xref>
                </sup> In the present work, we utilized a co-rotating TSP instrument having different heating zones in contrast to above listed previous reports.</p>
            <p>The goal of this work was to enhance the oral bioavailability of the BCS Class II drug, carvedilol by exploring the theory of SCS using a water-soluble crystalline carrier by employing TSP technology. The polyols (sorbitol and mannitol) were explored as crystalline carriers in the current study for SCS formation. Mannitol was screened as the main crystalline carrier owing to the higher enhancement in the solubility of the CAR in the crystalline suspension obtained with mannitol compared to sorbitol in the trials taken. The SCS of carvedilol using mannitol was prepared and evaluated by utilizing Design of experiments (DoE) methodology. Box-Behnken design (BBD) was utilized for the optimization wherein kneading zone temperature, screw speed, and CAR: mannitol ratio were selected as the independent factors, and solubility was the response. The aspects of 
                <italic toggle="yes">in-silico</italic> molecular dynamics (MD) were applied to study the interactions between the CAR and mannitol in different ratios of CAR: mannitol (20:80, 35:65, and 50:50) at various kneading zone temperatures (120&#x00b0;C, 130&#x00b0;C, and 140&#x00b0;C) to predict the optimal ratios for preparing CAR-SCS formulation which would yield higher solubility, on the basis of hydrophilicity and hydrophobicity report for all the formulated SCS formulations of CAR generated from 
                <italic toggle="yes">in-silico</italic> MD studies. Also, the stability of the experimentally optimized CAR-SCS (F8), was assessed using 
                <italic toggle="yes">in-silico</italic> MD studies. There are no reports available on the use of such 
                <italic toggle="yes">in-silico</italic> MD studies for the preparation of SCS. The DoE optimized CAR-SCS (F8) was characterized for different physicochemical properties 
                <italic toggle="yes">i.e.</italic> differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), powder X-ray Diffraction (P-XRD) and nuclear magnetic resonance (NMR) analysis. The CAR-SCS (F8) was subjected to 
                <italic toggle="yes">ex vivo</italic> permeation and 
                <italic toggle="yes">in vivo</italic> pharmacokinetic (PK) study to understand the dissolution and absorption rate of CAR.</p>
        </sec>
        <sec id="sec2" sec-type="methods">
            <title>Methods</title>
            <sec id="sec3">
                <title>Materials</title>
                <p>CAR was obtained as a gift sample from Zydus Cadila Healthcare Ltd, Kundaim, Goa, India. Mannitol and sorbitol were purchased from Universal Laboratories Private Ltd, Mumbai, India. Methanol, acetonitrile (ACN), Triethylamine (TEA) and ortho-phosphoric acid (OPA) were obtained from Loba Chemie Pvt Ltd (Mumbai, India). 0.22 &#x03bc; membrane filters were obtained from Chemixol agencies, Mangaluru. All the chemicals and solvents utilized were of analytical grade.</p>
            </sec>
            <sec id="sec4">
                <title>Selection of crystalline polyol for the preparation of solid crystal suspension of carvedilol</title>
                <p>A TSP instrument (O-Micron 10P, Steer Engineering, Bangalore, India) with co-rotating screws having an outer to the inner diameter (Do/Di) of 1.71 was utilized for the study. A few initial trials were taken using sorbitol and mannitol as hydrophilic carriers by preparing a 50:50 mixture using mortar and pestle. The TSP consisted of four zones (B1, B2, B3 and B4). The B1, B2 and B4 was set at 31&#x00b0;C, 100&#x00b0;C, 95&#x00b0;C respectively. The B3 (kneading zone) temperature range was selected as 70-110&#x00b0;C for sorbitol and 120-140&#x00b0;C for mannitol, considering the melting point of the crystalline polyols, and the screw rpm was varied from 50-150 rpm (
                    <xref ref-type="table" rid="T1">Table 1</xref>). From the results obtained by solubility studies for both the polyols, mannitol was screened as the primary hydrophilic carrier for formulating the CAR-SCS using DoE (
                    <xref ref-type="table" rid="T1">Table 1</xref>).</p>
                <table-wrap id="T1" orientation="portrait" position="float">
                    <label>Table 1. </label>
                    <caption>
                        <title>Preliminary trials conducted using sorbitol and mannitol as the hydrophilic carriers.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Hydrophilic carrier used</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Drug: Hydrophilic carrier ratio</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Kneading zone temperature</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Screw rpm</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Solubility (mg/mL)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="7" valign="top">Mannitol</td>
                                <td align="left" colspan="1" rowspan="7" valign="top">50:50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">120</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">0.548</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">120</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">75</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">0.650</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">130</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">0.820</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">130</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">0.887</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">130</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">150</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">1.003</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">140</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">0.382</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">140</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.400</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="4" valign="top">Sorbitol</td>
                                <td align="left" colspan="1" rowspan="4" valign="top">50:50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">80</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.310</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">80</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.538</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">110</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.420</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">110</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.822</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
            </sec>
            <sec id="sec5">
                <title>Formulation of Solid crystal suspension of Carvedilol (CAR-SCS) by TSP using BBD</title>
                <p>BBD was utilized to systematically evaluate the effect of TSP instrument parameters like kneading zone temperature, screw rpm, and formulation-related parameter (CAR: mannitol ratio) on the solubility of CAR from SCS formulations (response). The experimental runs and data analysis were performed utilizing Design-Expert software (Version 9.0.3.1) (
                    <ext-link ext-link-type="uri" xlink:href="https://www.ufla.br/chemoface/">Chemoface</ext-link> is a free alternative software that may be able to perform similar functions). ANOVA was utilized to find the significant effect of the factors on response regression coefficients.</p>
                <p>CAR and mannitol physical mixtures at the ratios of 50:50, 35:65, and 20:80 were prepared, blended using mortar and pestle, and extruded from the TSP die. The kneading zone temperature range of 120-140&#x00b0;C was used. The TSP zones B1, B2 and B4 were set at 32&#x00b0;C, 100&#x00b0;C and 95&#x00b0;C respectively. Zone B3 (kneading zone) temperature and screw rpm were set as per the runs suggested by the Design-Expert software (
                    <xref ref-type="table" rid="T2">Table 2</xref>).</p>
                <table-wrap id="T2" orientation="portrait" position="float">
                    <label>Table 2. </label>
                    <caption>
                        <title>Carvedilol-solid crystal suspension formulation trials generated by the Design-Expert software.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Serial. No.</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Formulation code</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Drug: mannitol ratio</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Kneading zone temperature (&#x00b0; C)</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Screw rpm</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Solubility (mg/mL)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">1</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F1</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50:50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">140</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.40</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F2</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">35:65</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">140</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">150</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.69</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F3</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">20:80</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">130</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">150</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.95</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F4</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">35:65</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">140</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.51</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F5</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50:50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">130</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">150</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.95</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">6</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F6</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">35:65</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">130</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.90</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">7</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F7</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">35:65</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">120</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">150</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.30</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">8</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F8</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">20:80</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">120</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.50</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">9</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F9</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">35:65</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">130</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.89</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">10</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F10</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">20:80</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">140</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.73</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">11</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F11</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50:50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">130</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.65</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">12</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F12</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">35:65</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">120</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.60</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">13</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F13</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50:50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">120</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.08</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">14</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F14</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">20:80</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">130</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">50</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.84</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">15</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">F15</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">35:65</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">130</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.90</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
            </sec>
            <sec id="sec6">
                <title>
                    <italic toggle="yes">In-silico</italic> studies for CAR-SCS</title>
                <p>The molecular dynamics (MD) simulation studies of CAR with mannitol at different ratios, 
                    <italic toggle="yes">i.e.</italic>, 50:50, 35:65, and 20:80 with different kneading zone temperatures, were performed using Schrodinger software Suite (version 2023-2) (Schrodinger LLC, New York) in the Maestro module (version 13.6.121, MMShareVersion 6.2.121, Release 2023-2, Platform Linux-x86_64) (An alternative free software able to perform similar tasks is 
                    <ext-link ext-link-type="uri" xlink:href="https://www.gromacs.org/">Gromacs</ext-link> RRID:SCR_014565). The guest molecule CAR and mannitol structures were built using the 2D sketcher and were optimized with LigPrep by using default settings at pH 7.0 coupled with Epik calculations. The optimization of the geometry of the CAR-SCS in the various ratios of CAR with mannitol (
                    <italic toggle="yes">i.e.</italic> 50:50, 35:65, and 20:80) was individually done utilizing the Macro Model minimization tool by keeping default settings.</p>
            </sec>
            <sec id="sec7">
                <title>Molecular structure preparation using Disordered System Builder (DSB)</title>
                <p>The two-dimensional structure of CAR and mannitol was built in the Maestro structure builder by referring to the Pubchem database (
                    <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Carvedilol">PubChem CID: 2585</ext-link>)
                    <sup>
                        <xref ref-type="bibr" rid="ref44">44</xref>
                    </sup> and (
                    <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/mannitol">PubChem CID: 6251</ext-link>).
                    <sup>
                        <xref ref-type="bibr" rid="ref45">45</xref>
                    </sup> The optimization of the structures was done by employing OPLS4 forcefield LigPrep/Epik.
                    <sup>
                        <xref ref-type="bibr" rid="ref18">18</xref>
                    </sup>
                </p>
                <p>CAR and mannitol were selected in DSB. In the components setting, 50 molecules of CAR with mannitol were prepared in the ratios: 20:80, 35:65, and 50:50. A new orthorhombic periodic boundary condition with dimension 40 &#x00c5; was created. Then OPLS4 force field was used to build the CAR-SCS, and all other settings were kept on default. The formed CAR-SCS was taken for MD simulation studies.</p>
            </sec>
            <sec id="sec8">
                <title>Molecular simulation studies and stability determination</title>
                <p>The Desmond Module (Version 22.4) of Schrodinger was utilized for running the MD simulations. The MD was conducted for 0, 25, 75, and 100 ns at different kneading zone temperatures used, 
                    <italic toggle="yes">i.e.</italic>, 395.15K (120&#x00b0;C), 403.15K (130&#x00b0;C), and 413.15K (140&#x00b0;C) with 1.013 bar pressure kept by utilizing the Nose Hoover Chain thermostat and Matrtyna-Tobias-Klein barostate. For studying the stability of the CAR-SCS, CAR binding mode to mannitol in the CAR-SCS at different CAR and mannitol ratios, 
                    <italic toggle="yes">i.e.</italic>, 20:80, 35:65, and 50:50 at different kneading zone temperatures, 
                    <italic toggle="yes">i.e.</italic>, 393.15 K (120&#x00b0;C), 403.15 K (130&#x00b0;C), 413.15 K (140&#x00b0;C), pressure (bar) 1.01325 and for 100 ns simulation time period was predicted; thus generating 1000 structural frames of SCS formulation which were saved in trajectory. The MD simulation was run on CAR and mannitol in the SCS. The trajectory generated after the simulations was utilized for calculating the root mean square deviation (RMSD) to show the stability of the optimal CAR-SCS formulation.</p>
            </sec>
            <sec id="sec9">
                <title>Percentage yield</title>
                <p>The CAR-SCS formulations were collected, and the practical yield (%) was found out employing the formula
                    <sup>
                        <xref ref-type="bibr" rid="ref3">3</xref>
                    </sup>:
                    <disp-formula id="e1">
                        <mml:math display="block">
                            <mml:mo>%</mml:mo>
                            <mml:mtext>yield</mml:mtext>
                            <mml:mo>=</mml:mo>
                            <mml:mfenced close=")" open="(">
                                <mml:mrow>
                                    <mml:mtext>Practical yield</mml:mtext>
                                    <mml:mo>/</mml:mo>
                                    <mml:mtext>theoretical yield</mml:mtext>
                                </mml:mrow>
                            </mml:mfenced>
                            <mml:mo>&#x00d7;</mml:mo>
                            <mml:mn>100</mml:mn>
                        </mml:math>
                    </disp-formula>
                </p>
            </sec>
            <sec id="sec10">
                <title>Differential scanning calorimetry (DSC)</title>
                <p>DSC analysis was done utilizing DSC-60 Plus with TA-60WS thermal analyzer (Shimadzu Corporation, Kyoto, Japan) for pure CAR, mannitol, physical mixture (PM) of CAR and mannitol at 1:1 ratio, and the DoE optimized CAR-SCS (F8), for the analysis of solid-state.
                    <sup>
                        <xref ref-type="bibr" rid="ref18">18</xref>
                    </sup> A 5 mg sample was enclosed in an aluminum pan and sealed. An empty pan was utilized as a blank. The heating of the samples was achieved at a of 10&#x00b0;C/min rate from room temperature to 300&#x00b0;C in a nitrogen environment at a 10 mL/min flow rate. The DSC thermograms were recorded for the individual samples.
                    <sup>
                        <xref ref-type="bibr" rid="ref46">46</xref>
                    </sup>
                </p>
            </sec>
            <sec id="sec11">
                <title>Thermogravimetry analysis (TGA)</title>
                <p>TGA was performed to evaluate the thermal stability of CAR, PM, and CAR-SCS (F8). The analysis was done using DTA-TG device (DTG-60H, Shimadzu Co., Japan). About 4 mg of the sample was heated between 25-800&#x00b0;C at a 10&#x00b0;C/min heating rate under dynamic nitrogen atmosphere. Experiments were done at the flow rate of 50 mL/min.</p>
            </sec>
            <sec id="sec12">
                <title>Fourier transform infrared (FTIR) spectroscopy</title>
                <p>FTIR spectra were recorded for pure CAR, mannitol, 1:1 PM of CAR and mannitol, and DoE optimized CAR-SCS (F8) using Alpha II, ECO-ATR (Bruker, Germany) at the wavelength range of 4000-900 cm
                    <sup>-1</sup> for investigation of interactions of the CAR and the mannitol. FTIR spectra was also recorded for the DoE-optimized F8 formulation. The powdered sample was placed on the stage, and a focused image was obtained. The images were obtained using OPUS 8.0 software (provided with the equipment used).</p>
            </sec>
            <sec id="sec13">
                <title>Powder X-ray diffraction (XRD) studies</title>
                <p>XRD was utilized to estimate the CAR&#x2019;s physical form in the CAR-SCS (F8) formulation. The instrument used was Malvern PANalytical, Netherlands, with Empyrean 3
                    <sup>rd</sup> generation model. X-ray diffraction was carried out for CAR, mannitol, CAR-mannitol physical mixture (ratio: 1:1), and optimized CAR-SCS (F8) formulation with a 40 kV voltage and 15 mA tube current at 7-50&#x00b0; (2&#x03b8;) range.
                    <sup>
                        <xref ref-type="bibr" rid="ref46">46</xref>
                    </sup>
                </p>
            </sec>
            <sec id="sec14">
                <title>Scanning electron microscopy (SEM) and energy dispersive spectroscopy (EDS)</title>
                <p>EVO MA18 with Oxford EDS (Zeiss, Germany) scanning electron microscope was utilized for assessing the surface morphology of plain CAR, plain mannitol, and optimized CAR-SCS (F8). The samples were placed onto the aluminum stub employing double-sided adhesive tape, and a vacuum at ten torr was applied. The samples were then scanned with an electron beam and SEM images were taken. Samples were tested utilizing both SEM and EDS.</p>
            </sec>
            <sec id="sec15">
                <title>Raman spectrometric analysis</title>
                <p>Raman spectrometric analysis was performed for the CAR, mannitol, and optimized CAR-SCS (F8) formulation using I-Raman Plus (B&amp;W TEK, Plainsboro, NJ, USA) fitted with an Ar-Ne instrument. For all the experiments, the excitation wavelength of 785 nm of 35 mW power was utilized, and the integration time was 10 sec.</p>
            </sec>
            <sec id="sec16">
                <title>Nuclear magnetic resonance (NMR) analysis</title>
                <p>Proton NMR (
                    <sup>1</sup>H) was done for CAR, mannitol, and the CAR-SCS (F8) by dissolving an appropriate amount of the samples separately in dimethyl sulfoxide, and the analysis was performed using a 400 MHz-Bruker ASCEND TM 400 NMR analyzer (Billerica, MA, USA).</p>
            </sec>
            <sec id="sec17">
                <title>Saturation solubility determination</title>
                <p>The saturation solubility of plain CAR and all the formulations was assessed in pH 6.8 phosphate buffer. Excess amounts of CAR and CAR-SCS formulations were separately incorporated in 2 mL of pH 6.8 phosphate buffer in the Eppendorf tubes, and the tubes were kept in a tube rotator (Neuation, 
                    <italic toggle="yes">i</italic> Roll PR35, Gandhinagar, Gujarat, India) for 48 h at 50 rpm speed. Later, the solutions were centrifuged at 10,000 rpm for 7 min. The supernatant was appropriately diluted and analyzed by a UV spectrophotometer at 241 nm.</p>
            </sec>
            <sec id="sec18">
                <title>Determination of flow properties</title>
                <p>The micrometric properties of CAR and optimized CAR-SCS (F8), including tap density, angle of repose, bulk density, and Hausner&#x2019;s ratio, were evaluated. Tap density and compressibility index were assessed by the tapping method. Tap density was estimated using tap density tester (Electrolab ETD-1020, Mumbai, Maharashtra, India). The CAR and CAR-SCS was transferred using a funnel to a graduated 100 mL cylinder. The weight was determined using weighing balance (Wensar,Bengaluru, India) and the volume was recorded visually for the bulk density determination. The cylinder was tapped 1000 times and tap density calculation was done according to the formula below.
                    <sup>
                        <xref ref-type="bibr" rid="ref19">19</xref>
                    </sup>
                    <sup>&#x2013;</sup>
                    <sup>
                        <xref ref-type="bibr" rid="ref22">22</xref>
                    </sup>
                    <disp-formula id="e2">
                        <mml:math display="block">
                            <mml:mtext>Bulk density</mml:mtext>
                            <mml:mo>=</mml:mo>
                            <mml:mfrac>
                                <mml:mtext>mass</mml:mtext>
                                <mml:mtext>bulk volume</mml:mtext>
                            </mml:mfrac>
                        </mml:math>
                    </disp-formula>
                    <disp-formula id="e3">
                        <mml:math display="block">
                            <mml:mi>Tap</mml:mi>
                            <mml:mspace width="0.25em"/>
                            <mml:mtext>density</mml:mtext>
                            <mml:mo>=</mml:mo>
                            <mml:mfrac>
                                <mml:mtext>mass</mml:mtext>
                                <mml:mtext>tapped volume</mml:mtext>
                            </mml:mfrac>
                        </mml:math>
                    </disp-formula>
                </p>
                <p>Hausner&#x2019;s ratio is the ratio of tap density to the bulk density. Carr&#x2019;s index (CI) is a measure of particle size, flow rate and cohesiveness. It was calculated using the formula:
                    <disp-formula id="e4">
                        <mml:math display="block">
                            <mml:mi>CI</mml:mi>
                            <mml:mo>=</mml:mo>
                            <mml:mfrac>
                                <mml:mfenced close=")" open="(">
                                    <mml:mrow>
                                        <mml:mi>Tap</mml:mi>
                                        <mml:mspace width="0.25em"/>
                                        <mml:mtext>density</mml:mtext>
                                        <mml:mo>&#x2212;</mml:mo>
                                        <mml:mtext>bulk density</mml:mtext>
                                    </mml:mrow>
                                </mml:mfenced>
                                <mml:mtext>Tapped density</mml:mtext>
                            </mml:mfrac>
                            <mml:mo>&#x00d7;</mml:mo>
                            <mml:mn>100</mml:mn>
                        </mml:math>
                    </disp-formula>
                </p>
                <p>The fixed funnel methodology was utilized for measuring the angle of repose
                    <sup>
                        <xref ref-type="bibr" rid="ref3">3</xref>
                    </sup> wherein a funnel was fixed onto a stand such that the funnel tip was 2.5 cm above the flat surface on which a graph paper was placed. The powders were allowed to freely fall until the tip of the heap touched the funnel. The radius and height of the heap was measured. The formula utilized for the calculation was as follows
                    <sup>
                        <xref ref-type="bibr" rid="ref20">20</xref>
                    </sup>
                    <sup>,</sup>
                    <sup>
                        <xref ref-type="bibr" rid="ref23">23</xref>
                    </sup>:
                    <disp-formula id="e5">
                        <mml:math display="block">
                            <mml:mo>&#x019f;</mml:mo>
                            <mml:mo>=</mml:mo>
                            <mml:msup>
                                <mml:mo>tan</mml:mo>
                                <mml:mrow>
                                    <mml:mo>&#x2212;</mml:mo>
                                    <mml:mn>1</mml:mn>
                                </mml:mrow>
                            </mml:msup>
                            <mml:mspace width="0.25em"/>
                            <mml:mfrac>
                                <mml:mtext>Pile height</mml:mtext>
                                <mml:mtext>Pile radius</mml:mtext>
                            </mml:mfrac>
                        </mml:math>
                    </disp-formula>
                </p>
            </sec>
            <sec id="sec19">
                <title>Drug content</title>
                <p>10 mg CAR-SCS were dissolved in little amount of methanol, and diluted using 0.1N HCl to 100 mL. This solution was sonicated using an ultrasonic bath (Antech,GT sonic, Panacea Instruments Pvt Ltd, New Delhi, Delhi, India) for 10 min. After diluting 0.1 mL of the solution to 1 mL with 0.1N HCl, it was filtered and analyzed using UV spectrophotometer (UV-1800 UV/Vis spectrophotometer, Shimadzu, Kyoto, Japan) at 241 nm
                    <sup>3</sup>.</p>
            </sec>
            <sec id="sec20">
                <title>
                    <italic toggle="yes"> In vitro</italic> dissolution study</title>
                <p>Dissolution studies were done utilizing USP type II dissolution apparatus (Electrolab TDT-08L Dissolution Tester) for CAR and all the CAR-SCS separately in both pH 1.2 HCl solution and phosphate buffer pH 6.8. Sodium lauryl sulfate (SLS) at 0.1% concentration was incorporated in both the dissolution solutions. A quantity of CAR and all CAR-SCS corresponding to 6.25 mg of CAR was loaded into the capsules of Size 4, and the capsules were placed in the 500 mL of dissolution medium maintained at 37 &#x00b1; 0.5&#x00b0;C with a 50-rpm paddle speed. 5mL of samples were taken at 0.25 h, 0.5 h, 0.75 h, 1 h, and 2 h, and the equivalent fresh medium was incorporated into the dissolution jar. The collected samples were filtered using 0.45 micron filter and were analyzed by utilizing a UV spectrophotometer at 241 nm.
                    <sup>
                        <xref ref-type="bibr" rid="ref3">3</xref>
                    </sup>
                    <sup>,</sup>
                    <sup>
                        <xref ref-type="bibr" rid="ref24">24</xref>
                    </sup>
                </p>
            </sec>
            <sec id="sec21">
                <title>Laboratory animals</title>
                <p>Eighteen healthy male Wistar rats (eight weeks old) with body weight of 200-250 g were utilized for this study. The 
                    <italic toggle="yes">ex vivo</italic> study (n=3 per group/experiment with two groups) and 
                    <italic toggle="yes">in vivo</italic> pharmacokinetic study protocol (n=4 per group with three groups) was approved by Institutional Animal Ethics committee, Kasturba Medical College, Manipal (IAEC Registration No.: 94/PO/RReBi/S/99/CPCSEA). The number of rats per group for the respective experiments was decided based upon the existing literature.
                    <sup>
                        <xref ref-type="bibr" rid="ref16">16</xref>
                    </sup>
                    <sup>,</sup>
                    <sup>
                        <xref ref-type="bibr" rid="ref25">25</xref>
                    </sup>
                    <sup>,</sup>
                    <sup>
                        <xref ref-type="bibr" rid="ref26">26</xref>
                    </sup> Each group consisted of four animals maintained in a cage for the 
                    <italic toggle="yes">in vivo</italic> pharmacokinetic studies and three animals per cage for 
                    <italic toggle="yes">ex vivo</italic> intestinal permeation studies at optimal conditions of 25&#x00b0;C and 50% RH with a 12 hour light/dark cycles with continuous access to reverse osmosis (RO) water and pellets rat food (VRK Nutritional Solutions, Sangli, Maharashtra, India). The cages were labelled with the individual experiment title and the group names prior to the start of experiment to avoid error. The experiments were conducted in accordance to the Committee for the purpose of control and supervision of Experiments on Animals (CPCSEA) rules.
                    <sup>
                        <xref ref-type="bibr" rid="ref47">47</xref>
                    </sup>
                </p>
            </sec>
            <sec id="sec22">
                <title>
                    <italic toggle="yes"> Ex vivo</italic> intestinal permeation studies</title>
                <p>The rats were randomly assigned to two groups 
                    <italic toggle="yes">i.e</italic> Group I: Plain CAR (n=3) and Group II: CAR-SCS (F8) (n=3). The number of animals per group was decided according to the existing literature.
                    <sup>
                        <xref ref-type="bibr" rid="ref26">26</xref>
                    </sup> These rats were euthanized ethically by giving an intraperitoneal injection of thiopental sodium overdose (50 mg/kg),
                    <sup>
                        <xref ref-type="bibr" rid="ref19">19</xref>
                    </sup>
                    <sup>,</sup>
                    <sup>
                        <xref ref-type="bibr" rid="ref26">26</xref>
                    </sup> and the abdominal area was shaved and an incision of 5 cm was done. The intestine was removed and the ileocaecal junction was identified. This segment was then cleaned thoroughly by using the blunt end of the syringe and transferred to the Petri plate with Kreb&#x2019;s Ringer buffer solution pH 7.4. This intestinal segment was then cut into pieces. One end was tightly tied with the thread. From the other side, 1 mL of the CAR, equivalent to 6.25 mg dispersed in the Kreb&#x2019;s Ringer buffer solution pH 7.4 was added. Another end of the intestinal segment was sealed. Similarly, 1 mL of the CAR-SCS (F8), equivalent to 6.25 mg dispersed in the Kreb&#x2019;s Ringer buffer solution pH 7.4, was added to another intestinal segment, followed by sealing of the intestine. The non-everted sacs were kept in 50 mL of Kreb&#x2019;s Ringer buffer solution pH 7.4 in a magnetic stirrer with a 50 rpm speed aerated with oxygen utilizing a laboratory aerator (Atlas Air Pump 6000, Mumbai, Maharashtra). The samples were taken from the serosal compartment, 
                    <italic toggle="yes">i.e.</italic>, outside the sac, at 20, 40, 60, 80, 120, and 180 min, and a similar quantity of the fresh medium was incorporated. The samples were analyzed by UV-spectroscopy after filtration using 0.45 micron filters. The permeability of CAR from the CAR-SCS (F8) was obtained from the plot of the cumulative amount of CAR permeated from the rat intestine 
                    <italic toggle="yes">vs.</italic> time in min. The apparent permeability coefficient calculation was done as per the 
                    <xref ref-type="disp-formula" rid="e6">Equation 1</xref> below.
                    <sup>
                        <xref ref-type="bibr" rid="ref27">27</xref>
                    </sup>
                    <disp-formula id="e6">
                        <mml:math display="block">
                            <mml:msub>
                                <mml:mi mathvariant="normal">P</mml:mi>
                                <mml:mi>app</mml:mi>
                            </mml:msub>
                            <mml:mo>=</mml:mo>
                            <mml:mfrac>
                                <mml:mi>F</mml:mi>
                                <mml:mrow>
                                    <mml:mi>A</mml:mi>
                                    <mml:mo>&#x00d7;</mml:mo>
                                    <mml:msub>
                                        <mml:mi mathvariant="normal">C</mml:mi>
                                        <mml:mn>0</mml:mn>
                                    </mml:msub>
                                </mml:mrow>
                            </mml:mfrac>
                        </mml:math>
                        <label>(1)</label>
                    </disp-formula>
                </p>
                <p>Where A refers to the cross-sectional area of the intestinal segment (cm
                    <sup>2</sup>), F refers to permeation flux, C
                    <sub>0</sub> is the initial CAR concentration in &#x03bc;g/ml</p>
            </sec>
            <sec id="sec23">
                <title>
                    <italic toggle="yes"> In vivo</italic> pharmacokinetic study</title>
                <p>The rats were classified into three groups with each group containing 4 animals ((n=4 per group; total number of groups: 3).</p>
                <p>Group A: Plain CAR (40 mg/kg)</p>
                <p>Group B: CAR-Mannitol PM (powder equivalent to 40 mg/kg of CAR)</p>
                <p>Group C: CAR-SCS (F8) formulation (powder equivalent to 40 mg/kg of CAR).</p>
                <p>All the above samples were administered orally in the form of 0.2% carboxy methyl cellulose suspension. At the time intervals of 0.5, 1, 2, 4, 6, 12 and 24 hours, 200 &#x03bc;L of blood was collected from the retroorbital plexus in the centrifuge tubes with 10% EDTA. 100 &#x03bc;L of plasma was collected by centrifugation at 10,000 rpm for 10 min.
                    <sup>
                        <xref ref-type="bibr" rid="ref16">16</xref>
                    </sup>
                    <sup>,</sup>
                    <sup>
                        <xref ref-type="bibr" rid="ref25">25</xref>
                    </sup>
                </p>
                <p>Plasma samples were analyzed for CAR by using high performance liquid chromatography (HPLC). The HPLC system (SHIMADZU LC2010-CHT, Schimadzu Corporation, Kyoto, Japan) with the dual piston pump, autosampler and a UV-visible detector was utilized. The obtained chromatograms were analyzed using the postrun icon in the LC solutions software version 5.57 (provided with the equipment used). The mobile phase utilized was Acetonitrile and water adjusted to pH 3.0 with trifluoroacetic acid (45:55). The flow rate used was 1 ml/min at the UV detector wavelength of 241 nm. A Kromasil C18 Reverse Phase column was utilized for the analysis.</p>
                <p>The plasma samples were processed by protein precipitation method. 300 &#x03bc;L of methanol (precipitation agent) was incorporated into the tubes and was centrifuged for 1 min utilizing vortex mixer. This was centrifuged at 10,000 rpm for 10 min and separation of the supernatant. The supernatant was injected in the HPLC system.
                    <sup>
                        <xref ref-type="bibr" rid="ref16">16</xref>
                    </sup>
                    <sup>,</sup>
                    <sup>
                        <xref ref-type="bibr" rid="ref28">28</xref>
                    </sup> The calibration plot for CAR in the plasma was plotted in the concentration range of 25 to 5,000 ng/mL, and showed a R
                    <sup>2</sup> value of 0.983, depicting its linearity with the equation y=0.0014x+0.0897, where &#x2018;x&#x2019; is the CAR conc. and &#x2018;y&#x2019; is the peak area ratio of CAR to IS (Quetiapine).</p>
            </sec>
            <sec id="sec24">
                <title>Stability studies</title>
                <p>Optimized CAR-SCS (F8) was incorporated into the hard gelatin capsules, and the capsules were stored in the glass bottle at 40&#x00b0;C/75% RH for three months in a stability chamber (Thermolab Scientific Equipments, 500 L capacity). The drug content and DSC analysis for the samples was done at intervals of one, two, and three months.</p>
            </sec>
        </sec>
        <sec id="sec25" sec-type="results|discussion">
            <title>Results and discussion</title>
            <sec id="sec26">
                <title>Preliminary trials</title>
                <p>Initial trials were taken using mannitol and sorbitol as hydrophilic carriers for the preparation of CAR-SCS. CAR: hydrophilic carrier at a 50:50 ratio was extruded through the TSP. The kneading zone (B3) temperatures of 120-140&#x00b0;C were selected for the preparation of CAR-mannitol SCS and 70-110&#x00b0;C was used for CAR-sorbitol SCS based on the melting point of the hydrophilic carriers. Initially, the effect of different kneading zone temperatures on the SCS was assessed. For CAR-mannitol SCS, with the increase in kneading zone temperature to 140&#x00b0;C the product formed was sticky, and the yield was much less owing to the loss of the product by sticking to the barrel. The increase in solubility was seen with the increase in kneading zone temperatures for CAR-mannitol and CAR-sorbitol.</p>
                <p>The impact of screw speed on the CAR-SCS was also examined. Screw speeds of 50-150 rpm were utilized. With an increase in the screw rpm to 150 rpm, the product yield was found to be more due to the decreased residence time in the TSP barrel resulting in the extrusion of fine powder. Additionally, the solubility of the product also enhanced which might be because of the increased surface area and improved interaction of the polymer with the drug at higher temperature. The solubility was found to be significantly enhanced with mannitol compared to sorbitol. Hence mannitol was selected as the hydrophilic carrier for preparing the CAR-SCS. From the initial trials (
                    <xref ref-type="table" rid="T1">Table 1</xref>), screw speed and the kneading zone temperature were found to have an effect on the solubility.</p>
            </sec>
            <sec id="sec27">
                <title>Experimental design</title>
                <p>BBD was employed to examine the influence of the three factors 
                    <italic toggle="yes">i.e.</italic>, CAR: mannitol ratio, kneading zone (B3) temperature, and screw rpm, on the solubility in 15 runs. The CAR: mannitol ratios selected were 20:80, 35:65, and 50:50. The kneading zone temperature and screw rpm ranged from 120-140&#x00b0;C and 50-150 rpm, respectively. The response variable was the solubility of CAR. For generating the statistical experimental design, Design Expert v.9.0.3.1 software was used. Different trials generated by Design Expert Software (R1 to R15), using the factors CAR: mannitol ratio, kneading zone temperature, and screw rpm, and the corresponding response, solubility is depicted in 
                    <xref ref-type="table" rid="T2">Table 2</xref>. The ANOVA results depicted that the model is significant with a F value of 34.47 and a p-value of &lt;0.0001.</p>
            </sec>
            <sec id="sec28">
                <title>Statistical analysis and optimization using BBD</title>
                <p>The 3D response surface plots are shown in 
                    <xref ref-type="fig" rid="f1">Figure 1</xref>. The CAR: mannitol ratio, kneading zone temperature, and screw rpm were found to affect the solubility of CAR significantly. The response factor solubility was found to increase with decreasing kneading zone temperatures and increasing screw rpm. Solubility was slightly affected by the CAR: mannitol ratio and showed a slight decrease with the increase in CAR: mannitol ratio. As the CAR: mannitol ratio increases, there is insufficient coverage of the drug particles by the water soluble carrier, causing a decrease in wettability and solubility.
                    <sup>
                        <xref ref-type="bibr" rid="ref29">29</xref>
                    </sup> ANOVA analysis was done to estimate the effect of individual factors on the response. For the response, individual factors and model sum of squares was computed for linear, 2-factor interaction, quadratic and cubic models. Model F-value of 34.47 and 
                    <italic toggle="yes">p</italic> values less than 0.05 indicated that the model terms are significant. A linear model was selected. The 
                    <italic toggle="yes">R
                        <sup>2</sup>
                    </italic> value for the selected model was found to be 0.904. The coded equation in terms of the actual factors generated by DoE was as follows:
                    <disp-formula id="e7">
                        <mml:math display="block">
                            <mml:mo>ln</mml:mo>
                            <mml:mfenced close=")" open="(">
                                <mml:mtext>solubility</mml:mtext>
                            </mml:mfenced>
                            <mml:mo>=</mml:mo>
                            <mml:mo>&#x2212;</mml:mo>
                            <mml:mn>0.0290</mml:mn>
                            <mml:mo>&#x2212;</mml:mo>
                            <mml:mn>0.0921</mml:mn>
                            <mml:mo>&#x00d7;</mml:mo>
                            <mml:mfenced close=")" open="(">
                                <mml:mrow>
                                    <mml:mi mathvariant="normal">C</mml:mi>
                                    <mml:mo>:</mml:mo>
                                    <mml:mi mathvariant="normal">M</mml:mi>
                                </mml:mrow>
                            </mml:mfenced>
                            <mml:mo>&#x2212;</mml:mo>
                            <mml:mn>0.248</mml:mn>
                            <mml:mo>&#x00d7;</mml:mo>
                            <mml:mi>KZT</mml:mi>
                            <mml:mo>+</mml:mo>
                            <mml:mn>0.0634</mml:mn>
                            <mml:mo>&#x00d7;</mml:mo>
                            <mml:mi>rpm</mml:mi>
                        </mml:math>
                    </disp-formula>
                </p>
                <fig fig-type="figure" id="f1" orientation="portrait" position="float">
                    <label>Figure 1. </label>
                    <caption>
                        <title>Response surface plot indicating the influence of (A) kneading zone temperature, (B) Drug: carrier ratio, and (C) screw rpm on solubility.</title>
                    </caption>
                    <graphic id="gr1" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure1.gif"/>
                </fig>
                <p>Where C:M represents CAR:mannitol ratio, KZT represents kneading zone temperature and rpm represents screw rpm.</p>
                <p>The validation of the model was done by performing the trial generated by the DoE software and calculating % residual by using the 
                    <xref ref-type="disp-formula" rid="e8">Equation 2</xref>:
                    <disp-formula id="e8">
                        <mml:math display="block">
                            <mml:mo>%</mml:mo>
                            <mml:mtext>residual</mml:mtext>
                            <mml:mo>=</mml:mo>
                            <mml:mfrac>
                                <mml:mrow>
                                    <mml:mtext>Predicted results</mml:mtext>
                                    <mml:mo>&#x2212;</mml:mo>
                                    <mml:mtext>Observed results</mml:mtext>
                                </mml:mrow>
                                <mml:mtext>Predicted results</mml:mtext>
                            </mml:mfrac>
                            <mml:mo>&#x00d7;</mml:mo>
                            <mml:mn>100</mml:mn>
                        </mml:math>
                        <label>(2)</label>
                    </disp-formula>
                </p>
                <p>The validation trial conducted using the 20:80 ratio of Drug: mannitol at a kneading zone temperature of 120&#x00b0;C showed a saturation solubility of 2.45. The solubility predicted by the software was 2.1 mg/mL. This accounted for the % residual of &#x00b1;14.3%. The DoE software showed the desirability for the optimized factors as 1.00.</p>
            </sec>
            <sec id="sec29">
                <title>Molecular dynamic (MD) simulation studies at different kneading zone temperatures, stability determination, and trajectory analysis</title>
                <p>In the starting phase of MD simulation, the CAR-SCS was stabilized. According to the hydrophilic and hydrophobic report generated for all CAR-SCS from the 
                    <italic toggle="yes">in-silico</italic> MD studies, as depicted in the 
                    <xref ref-type="table" rid="T3">Table 3</xref>, the CAR-SCS with a 20:80 ratio of CAR: mannitol, prepared at the kneading zone temperatures of 120&#x00b0;C, 130&#x00b0;C and those prepared with 35:65 ratio of CAR:mannitol with the kneading zone temperatures of 120&#x00b0;C, 140&#x00b0;C were predicted to be the optimal ones which could enhance the CAR solubility. These CAR-SCS were found to show more hydrophilicity and less hydrophobicity compared to the other CAR-SCS as per the 
                    <italic toggle="yes">in-silico</italic> hydrophilic and hydrophobic report.</p>
                <table-wrap id="T3" orientation="portrait" position="float">
                    <label>Table 3. </label>
                    <caption>
                        <title>Hydrophilic and hydrophobic report form Molecular Dynamics simulation studies.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Ratios of drug: mannitol</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Kneading zone temperature (&#x00b0;C)</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Hydrophilic portion</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Hydrophobic portion</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">20:80</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">120</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">2582.11</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">688.86</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">20:80</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">130</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">2140.41</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">529.47</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">20:80</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">140</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">2496.22</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">676.12</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">35:65</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">120</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">2804.52</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">819.49</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">35:65</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">130</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">2833.62</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">999.50</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">35:65</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">140</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">2914.20</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">734.13</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">50:50</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">120</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">2155.27</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">1032.32</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">50:50</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">130</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">2255.051</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">893.723</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">50:50</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">140</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">2622.993</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">1123.653</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
                <p>The results of the 
                    <italic toggle="yes">in-silico</italic> molecular simulation studies were similar to the experimental results. As per the experimental results, the CAR-SCS formulation prepared using a 20:80 ratio of CAR: mannitol at the kneading zone temperatures of 120&#x00b0;C showed the best results. The hydrophilicity and hydrophobicity generated from the 
                    <italic toggle="yes">in-silico</italic> MD studies of the CAR-SCS (F8) prepared using 20:80 ratio of CAR: mannitol at the kneading zone temperatures of 120&#x00b0;C is depicted in 
                    <xref ref-type="fig" rid="f2">Figure 2</xref>. As illustrated by the molecular simulation studies, hydrophilic portion is represented in white color and the orange color depicts the hydrophobic portion. The hydrophilicity and hydrophobicity of all the CAR-SCS formulations predicted by 
                    <italic toggle="yes">in silico</italic> MD studies are illustrated in 
                    <xref ref-type="table" rid="T3">Table 3</xref>. For assessing the stability of the CAR-SCS structures during the MD simulation, the structures from the trajectory were aligned with mannitol atoms, and the root mean square deviation (RMSD) calculation was done separately for CAR and CAR-SCS at different temperatures and ratios with respect to the preliminary frame. The fluctuation in the RMSD values was found to be less than 5&#x00c5;. This indicated a very low fluctuation showing the stability of CAR-SCS complex. 
                    <xref ref-type="fig" rid="f3">Figure 3</xref> demonstrates the MD simulation done for the CAR-SCS formulation prepared using a 20:80 ratio of CAR: mannitol at the kneading zone temperatures of 120&#x00b0;C. The RMSD graphs were plotted for the original CAR structure and the MD simulation computed structures of optimum CAR-SCS. The RMSD plots for optimum CAR-SCS prepared using a 20:80 ratio of CAR: mannitol at the kneading zone temperatures of 120&#x00b0;C are indicated in 
                    <xref ref-type="fig" rid="f4">Figure 4</xref>. The MD simulation studies showed the stability of the CAR-SCS with the least fluctuation in the RMSD values.</p>
                <fig fig-type="figure" id="f2" orientation="portrait" position="float">
                    <label>Figure 2. </label>
                    <caption>
                        <title>The hydrophilicity and hydrophobicity of the Carvedilol-solid crystal suspension prepared using 20:80 ratio of carvedilol: mannitol at the kneading zone temperature of 120 &#x00b0;C.</title>
                        <p>(Hydrophilic portion is represented in white color and the orange color depicts the hydrophobic portion).</p>
                    </caption>
                    <graphic id="gr2" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure2.gif"/>
                </fig>
                <fig fig-type="figure" id="f3" orientation="portrait" position="float">
                    <label>Figure 3. </label>
                    <caption>
                        <title>Molecular Dynamic simulation for the Carvedilol-solid crystal suspension prepared using 20:80 ratio of Carvedilol: mannitol at the kneading zone temperatures of 120 &#x00b0;C for 0 ns, 25 ns, 50 ns, 75 ns, and 100 ns.</title>
                    </caption>
                    <graphic id="gr3" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure3.gif"/>
                </fig>
                <fig fig-type="figure" id="f4" orientation="portrait" position="float">
                    <label>Figure 4. </label>
                    <caption>
                        <title>Root mean square deviation (RMSD) plotted in between the original carvedilol structure and the structures computed during molecular dynamic simulation of Carvedilol-Solid crystal suspension prepared using 20:80 ratio of carvedilol: mannitol at the kneading zone temperature of 120 &#x00b0;C.</title>
                    </caption>
                    <graphic id="gr4" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure4.gif"/>
                </fig>
            </sec>
            <sec id="sec30">
                <title>Characterization</title>
                <p>
                    <bold>
                        <italic toggle="yes">Differential scanning calorimetry (DSC)</italic>
                    </bold>
                </p>
                <p>DSC thermograms of CAR, mannitol, PM, and the CAR-SCS (F8) are depicted in 
                    <xref ref-type="fig" rid="f5">Figure 5</xref>. A sharp endotherm at 117.67 &#x00b0;C was observed for CAR revealing the crystallinity of the drug. Mannitol exhibited a characteristic endotherm at 171.66&#x00b0;C, confirming the crystallinity of mannitol. Two melting endotherms were seen in the DSC spectra of the PM and the CAR-SCS (F8). In CAR-SCS (F8), the melting endotherm of mannitol and the CAR were less intense and was slightly shifted to the low temperature compared to the plain mannitol. This was attributed to the presence of the molten form of mannitol reducing the melting point of higher melting point substances.
                    <sup>
                        <xref ref-type="bibr" rid="ref4">4</xref>
                    </sup>
                    <sup>,</sup>
                    <sup>
                        <xref ref-type="bibr" rid="ref5">5</xref>
                    </sup> The DSC results for the CAR-SCS (F8) indicate that both components occur as distinct crystalline phases. The least melting point depression shows that mannitol creates a very poor solvating environment for CAR but is effective in aiding the efficient wetting of the CAR.
                    <sup>
                        <xref ref-type="bibr" rid="ref4">4</xref>
                    </sup>
                </p>
                <fig fig-type="figure" id="f5" orientation="portrait" position="float">
                    <label>Figure 5. </label>
                    <caption>
                        <title>Differential Scanning Calorimetry (DSC) spectra of different samples.</title>
                        <p>Physical mixture-Carvedilol: mannitol physical mixture CAR-SCS-Optimized Carvedilol-solid crystal suspension (F8).</p>
                    </caption>
                    <graphic id="gr5" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure5.gif"/>
                </fig>
                <p>
                    <bold>
                        <italic toggle="yes">Thermogravimetry analysis (TGA)</italic>
                    </bold>
                </p>
                <p>TGA was performed to assess the thermal stability of CAR, PM and CAR-SCS (F8). The TGA curves of CAR, PM and the CAR-SCS (F8) are shown in 
                    <xref ref-type="fig" rid="f6">Figure 6</xref> which shows that a slight loss in the weight by 5% w/w for all the samples was observed at 245-275&#x00b0;C which is due to the presence of absorbed water and water of crystallization. The TGA curve revealed that the drug is thermally stable up to 222&#x00b0;C which is similar to the previously reported value.
                    <sup>
                        <xref ref-type="bibr" rid="ref30">30</xref>
                    </sup> The decomposition range of carvedilol was from 300-800&#x00b0;C.
                    <sup>
                        <xref ref-type="bibr" rid="ref31">31</xref>
                    </sup> The decomposition of PM containing the CAR and mannitol started at 219&#x00b0;C and for F8 formulation, the decomposition started at 245&#x00b0;C. At the temperatures above 300&#x00b0;C, the samples showed 70% of weight loss.</p>
                <fig fig-type="figure" id="f6" orientation="portrait" position="float">
                    <label>Figure 6. </label>
                    <caption>
                        <title>Thermogravimetry analysis thermograms of (i) Carvedilol (ii) Carvedilol -mannitol Physical mixture and (iii) Carvedilol -Solid crystal suspension (F8).</title>
                    </caption>
                    <graphic id="gr6" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure6.gif"/>
                </fig>
            </sec>
            <sec id="sec31">
                <title>Fourier transform infrared (FTIR) spectroscopy</title>
                <p>The overlay FTIR spectra of CAR, mannitol, PM, and CAR-SCS (F8) is illustrated in 
                    <xref ref-type="fig" rid="f7">Figure 7</xref>. FTIR spectrum of CAR exhibited typical peaks as reported previously in the literature
                    <sup>
                        <xref ref-type="bibr" rid="ref32">32</xref>
                    </sup>: a peak at 3342.33 cm
                    <sup>-1</sup> depicting the &#x2013;N-H stretch; the C-H stretch in the region is 2922.83 cm
                    <sup>-1</sup>; the peaks from 1251.69 cm
                    <sup>-1</sup> to 1453.40 cm
                    <sup>-1</sup> relating to the C-C stretch were observed. The band from 1453.4 cm
                    <sup>-1</sup> to 1501.8 cm
                    <sup>-1</sup> was allocated to C=C stretch. The FTIR spectra of mannitol exhibited the characteristic peaks as reported earlier in literature
                    <sup>
                        <xref ref-type="bibr" rid="ref33">33</xref>
                    </sup> with a peak at 2948.06 cm
                    <sup>-1</sup> depicting the &#x2013;C-H group, and at 1077.66 cm
                    <sup>-1</sup> depicting the C-O stretch. The sharp characteristic peak of CAR at 3342.33 cm
                    <sup>-1,</sup> which could be seen even in the 1:1 physical mixture of CAR and mannitol, was found to show decreased intensity in the CAR-SCS (F8) indicating the new product formation. Also, the disappearance of some peaks and a shift in the peaks to the lower intensity suggested the CAR-SCS formation.</p>
                <fig fig-type="figure" id="f7" orientation="portrait" position="float">
                    <label>Figure 7. </label>
                    <caption>
                        <title>Fourier Transform Infrared (FTIR) spectra of different samples.</title>
                        <p>Physical mixture-Carvedilol: mannitol physical mixture, CAR-SCS: Optimized Carvedilol-solid crystal suspension (F8).</p>
                    </caption>
                    <graphic id="gr7" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure7.gif"/>
                </fig>
            </sec>
            <sec id="sec32">
                <title>Powder X-ray diffraction (XRD) studies</title>
                <p>Powder XRD is a sensitive technique and has been considered a standard method for phase identification as the PXRD pattern is directly linked with the crystal structure of the materials. The significant change in the XRD patterns represents the change in the phase composition.
                    <sup>
                        <xref ref-type="bibr" rid="ref34">34</xref>
                    </sup> The XRD patterns of CAR, mannitol, physical mixture of CAR-mannitol, and CAR-SCS (F8) are depicted in 
                    <xref ref-type="fig" rid="f8">Figure 8</xref>. The XRD patterns of CAR, mannitol, CAR-mannitol physical mixture, and CAR-SCS (F8) were found to be sharp, confirming their crystalline nature.</p>
                <fig fig-type="figure" id="f8" orientation="portrait" position="float">
                    <label>Figure 8. </label>
                    <caption>
                        <title>X-ray diffraction (XRD) pattern of different samples.</title>
                        <p>Physical mixture-Carvedilol: mannitol physical mixture Carvedilol-Solid crystal suspension: Optimized CAR-SCS (F8).</p>
                    </caption>
                    <graphic id="gr8" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure8.gif"/>
                </fig>
                <p>The PM indicated less intensity of the CAR diffraction peaks suggesting the presence of CAR in the crystalline form and displayed less interaction with the mannitol. 2&#x03b8; values for the CAR-SCS (F8) were different from the starting materials. Also, the number of peaks, intensity and the positions of the diffraction peaks for CAR-SCS (F8) were less compared to the starting materials indicating the interaction between CAR and mannitol to form CAR-SCS.</p>
            </sec>
            <sec id="sec33">
                <title>Scanning electron microscopy (SEM) and energy dispersive spectroscopy (EDS)</title>
                <p>The SEM images of CAR, mannitol, PM and CAR-SCS (F8) are presented in 
                    <xref ref-type="fig" rid="f9">Figure 9</xref>. From the SEM analysis, it was observed that CAR showed an irregular shape with a very smooth surface. Mannitol showed needle-like morphology. The physical mixture was more of a mixture of CAR with the hydrophilic carrier mannitol. The SEM image of the formulation revealed consistent dispersion of the CAR in the melted carrier matrix. The data obtained from EDS is illustrated in 
                    <xref ref-type="table" rid="T4">Table 4</xref>. The EDS data for the extruded SCS formulation displayed the presence of carbon, nitrogen, and oxygen in the chemical structure of the CAR and hydrophilic carrier, as can be observed in 
                    <xref ref-type="fig" rid="f10">Figure 10</xref>. Since, mannitol does not contain nitrogen, the presence of nitrogen in the CAR-SCS (F8) formulation was concluded to have come from the CAR.</p>
                <fig fig-type="figure" id="f9" orientation="portrait" position="float">
                    <label>Figure 9. </label>
                    <caption>
                        <title>Scanning electron microscopy (SEM) images.</title>
                        <p>A: Carvedilol; B: Mannitol; C: Carvedilol:Mannitol Physical Mixture; D: Carvedilol-Solid crystal suspension (F8).</p>
                    </caption>
                    <graphic id="gr9" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure9.gif"/>
                </fig>
                <table-wrap id="T4" orientation="portrait" position="float">
                    <label>Table 4. </label>
                    <caption>
                        <title>Energy dispersive spectroscopy (EDS Data for Carvedilol -Solid crystal suspension (F8).</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Element</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">% weight</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Atomic weight</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">Carbon (C)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">58.54 &#x00b1; 1.48</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">65.15</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">Nitrogen (N)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.63 &#x00b1; 2.07</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.55</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">Oxygen (O)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">39.83 &#x00b1; 1.18</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">33.28</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">Total</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100.00</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100.00</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
                <fig fig-type="figure" id="f10" orientation="portrait" position="float">
                    <label>Figure 10. </label>
                    <caption>
                        <title>Energy dispersive spectroscopy (EDS) for the optimized Carvedilol-Solid crystal suspension (F8) formulation.</title>
                    </caption>
                    <graphic id="gr10" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure10.gif"/>
                </fig>
            </sec>
            <sec id="sec34">
                <title>Raman spectroscopy</title>
                <p>The Raman spectra of CAR, mannitol, physical mixture, and the CAR-SCS (F8) are illustrated in 
                    <xref ref-type="fig" rid="f11">Figure 11</xref>. Raman analysis was done to understand the distribution of the CAR in the carrier, and to determine the crystallinity of the CAR in the optimized CAR-SCS (F8) formulation. Usually, CAR shows well-defined peaks in the Raman spectra owing to its crystallinity, whereas the broad spectra is observed if the drug is in the amorphous form.
                    <sup>
                        <xref ref-type="bibr" rid="ref35">35</xref>
                    </sup> The Raman spectra of CAR were found to show sharp peaks characteristic of CAR.
                    <sup>
                        <xref ref-type="bibr" rid="ref35">35</xref>
                    </sup>
                    <sup>,</sup>
                    <sup>
                        <xref ref-type="bibr" rid="ref36">36</xref>
                    </sup> The carrier mannitol was also found to exhibit sharp peaks, as reported in the literature.
                    <sup>
                        <xref ref-type="bibr" rid="ref37">37</xref>
                    </sup> The optimized CAR-SCS (F8) were found to show sharp peaks similar to the CAR and mannitol, indicating the crystallinity of the starting materials and their mixture. The optimized CAR-SCS (F8) showed the distribution of crystalline CAR in the mannitol carrier, showing the presence of characteristic peaks present in CAR and mannitol.</p>
                <fig fig-type="figure" id="f11" orientation="portrait" position="float">
                    <label>Figure 11. </label>
                    <caption>
                        <title>Raman Spectroscopic data of different samples; Physical mixture-Carvedilol:mannitol physical mixture, CAR-SCS: Optimized Carvedilol-Solid crystal suspension (F8).</title>
                    </caption>
                    <graphic id="gr11" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure11.gif"/>
                </fig>
            </sec>
            <sec id="sec35">
                <title>Nuclear magnetic resonance (NMR) analysis</title>
                <p>CAR, mannitol and optimized CAR-SCS (F8) were characterized by NMR analysis (
                    <xref ref-type="fig" rid="f12">Figure 12</xref>). A sharp singlet obtained for the sample, CAR at 3.75 ppm was assigned to the three protons of &#x2013;CH
                    <sub>3</sub> group. The multiplets at 6.895-6.942 ppm and 6.680-6.852 ppm owing to the presence of four aromatic protons were seen. The multiplets at 2.859-2.946 ppm and 4.021-4.139 ppm were because of the two &#x2013;CH
                    <sub>2</sub> protons. -NH amine proton displayed a singlet at 2 ppm. &#x2013;NH indole proton showed a singlet at 11.26 ppm, and a &#x2013;OH proton showed a doublet at 5.175-5.183 ppm. The four protons from the indole rings showed four doublets at 7.356-7.442, 6.680-6.700, 7.274-7.293, and 7.066-7.085 ppm. A doublet at 8.221-8.241 was assigned to the isolated proton of the indole ring.
                    <sup>
                        <xref ref-type="bibr" rid="ref38">38</xref>
                    </sup>
                </p>
                <fig fig-type="figure" id="f12" orientation="portrait" position="float">
                    <label>Figure 12. </label>
                    <caption>
                        <title>Nuclear magnetic resonance (NMR) spectra of Carvedilol, mannitol and optimized Carvedilol-Solid crystal suspension formulation CAR-SCS(F8).</title>
                    </caption>
                    <graphic id="gr12" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure12.gif"/>
                </fig>
                <p>The NMR spectra of mannitol showed the characteristic hydrogens bonded to the oxygen at 4.140, 4.342, and 4.427 ppm. The symmetrical hydrogens of mannitol were detected at 3.380 ppm, 3.462 ppm, 3.525 ppm, and 3.604 ppm.
                    <sup>
                        <xref ref-type="bibr" rid="ref39">39</xref>
                    </sup> The 
                    <sup>1</sup>H NMR spectra of the CAR-SCS (F8) visibly depicted presence of proton signals of CAR and mannitol, indicating the non-covalent interaction between CAR and mannitol, thus forming CAR-SCS.</p>
            </sec>
            <sec id="sec36">
                <title>Saturation solubility studies</title>
                <p>The solubility of CAR in pH 6.8 buffer after 48 hours was estimated to be 0.05 mg/mL, which was similar to the earlier reported value.
                    <sup>
                        <xref ref-type="bibr" rid="ref40">40</xref>
                    </sup> The CAR-SCS (F8) showed solubility of 2.5 mg/mL, as illustrated in 
                    <xref ref-type="fig" rid="f13">Figure 13</xref>. CAR-SCS (F8) showed a 50-fold increase in solubility, probably because of the hydrophilic nature of mannitol facilitating wetting and hydration of the poorly soluble drug.
                    <sup>
                        <xref ref-type="bibr" rid="ref41">41</xref>
                    </sup> Molten mannitol acts as a hydrophilic carrier for CAR in the twin screw processing process, thus intimately mixing with CAR and surrounding it, resulting in improved solubility by enhancing the wetting of drug particles and increasing the surface area compared to the plain CAR.
                    <sup>
                        <xref ref-type="bibr" rid="ref41">41</xref>
                    </sup> The increase in the solubility seen for the CAR-SCS was much higher compared to the previously reported studies.
                    <sup>
                        <xref ref-type="bibr" rid="ref3">3</xref>
                    </sup>
                    <sup>,</sup>
                    <sup>
                        <xref ref-type="bibr" rid="ref42">42</xref>
                    </sup>
                </p>
                <fig fig-type="figure" id="f13" orientation="portrait" position="float">
                    <label>Figure 13. </label>
                    <caption>
                        <title>Saturation solubility of Plain Carvedilol and Carvedilol-solid Crystal suspension formulations.</title>
                    </caption>
                    <graphic id="gr13" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure13.gif"/>
                </fig>
            </sec>
            <sec id="sec37">
                <title>Determination of flow properties of the optimized CAR-SCS (F8) formulation</title>
                <p>The flow properties of the CAR-SCS (F8), including tap density, angle of repose, bulk density, and Hausner&#x2019;s ratio, were evaluated. These parameters were compared with the pure CAR. The parameters for the plain CAR and the CAR-SCS (F8) are illustrated in the 
                    <xref ref-type="table" rid="T5">Table 5</xref>. The angle of repose for pure CAR showed a value of 47.6&#x00b0;, indicating poor flow. The compressibility index was 24.2% and Hausner&#x2019;s ratio was 1.32 for the pure drug indicating passable flow. The CAR-SCS (F8) showed an excellent angle of repose of 25.73&#x00b0;, indicating considerably improved flow properties. The compressibility index and Hausner&#x2019;s ratio of CAR-SCS (F8) formulation were 20.2% and 1.25, respectively demonstrating fair flow properties.
                    <sup>
                        <xref ref-type="bibr" rid="ref43">43</xref>
                    </sup> These results indicated improved micromeritic properties in the CAR-SCS (F8) in comparison with pure CAR.</p>
                <table-wrap id="T5" orientation="portrait" position="float">
                    <label>Table 5. </label>
                    <caption>
                        <title>Flow properties of Carvedilol and Carvedilol-solid Crystal suspension (F8) formulation.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Parameters</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Pure CAR</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Optimized CAR-SCS (F8)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">Bulk density (g/mL)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.25</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.16</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">Tapped density (g/mL)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.33</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.19</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">Angle of repose</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">47.60</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">25.73</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">Compressibility index (%)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">24.20%</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">20.20%</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">Hausner&#x2019;s ratio</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.32</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">1.25</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
            </sec>
            <sec id="sec38">
                <title>Practical yield and drug content</title>
                <p>The practical percent yield for all the CAR-SCS formulations was found to be between 20.40 to 91.4%. The content of the CAR in all the SCS formulations ranged from 51.20-99.49%. The % practical yield and drug content of all the CAR-SCS is depicted in 
                    <xref ref-type="table" rid="T6">Table 6</xref>. Formulations F8 and F3 showed better % yield and drug content, respectively.</p>
                <table-wrap id="T6" orientation="portrait" position="float">
                    <label>Table 6. </label>
                    <caption>
                        <title>Percentage practical yield and Percent drug content for all Carvedilol-solid crystal suspension formulations.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">Formulation code</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Percentage yield (%)</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Percent drug content (%)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F1</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">21.20</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">74.20</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F2</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">48.00</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">65.55</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F3</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">72.90</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">99.49</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F4</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">41.00</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">63.99</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F5</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">32.20</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">96.70</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F6</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">26.60</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">83.20</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F7</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">22.20</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">56.10</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F8</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">91.60</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">77.75</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F9</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">20.40</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">55.72</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F10</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">46.10</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">73.14</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F11</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">28.10</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">60.00</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F12</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">64.90</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">51.20</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F13</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">43.50</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">85.64</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F14</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">33.80</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">64.57</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="middle">F15</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">14.60</td>
                                <td align="left" colspan="1" rowspan="1" valign="middle">54.97</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
            </sec>
            <sec id="sec39">
                <title>
                    <italic toggle="yes"> In vitro</italic> dissolution study</title>
                <p>The dissolution study was conducted in pH 1.2 of HCl solution as well as phosphate buffer solution of pH 6.8. Sodium lauryl sulfate (SLS) was incorporated in the dissolution medium as the addition of surfactant helps to accelerate the dissolution rate by acting as solubilizing agents.
                    <sup>
                        <xref ref-type="bibr" rid="ref40">40</xref>
                    </sup> The dissolution characteristics of all the formulations indicated a better dissolution rate than the bulk drug in both pH 1.2 and pH 6.8 buffer (
                    <xref ref-type="fig" rid="f14">Figure 14</xref>). The comparative dissolution profiles of the drug and the CAR-SCS (F8) formulation in pH 1.2 HCl solution and pH 6.8 buffers are represented in 
                    <xref ref-type="fig" rid="f15">Figure 15</xref> (A) and (B). The 
                    <italic toggle="yes">in vitro</italic> dissolution studies for the CAR-SCS (F8) revealed a 6.03- and 3.40-times enhancement in dissolution rate as compared to the plain CAR in pH 1.2 HCl solution and pH 6.8 phosphate buffer respectively. Release of pure CAR was found to be 14.90 &#x00b1; 0.98% in 120 min in pH 1.2 HCl solution and 28.65 &#x00b1; 1.8% in 120 min from pH 6.8 buffer. The release of CAR from the CAR-SCS (F8) was found to be 89.85 &#x00b1; 1.35 % in 120 min in pH 1.2 HCl solution and 94.4 &#x00b1; 1.5 % in 120 min in pH 6.8 buffer. A high dissolution rate of the CAR-SCS (F8) compared to the CAR can be attributed to the formation of SCS, wherein the crystalline drug is suspended in the melted crystalline hydrophilic carrier. The presence of the crystalline hydrophilic carrier around CAR enhances the polarity and decreases the interfacial tension between CAR and the dissolution medium, thus improving the dissolution rate and solubility.
                    <sup>
                        <xref ref-type="bibr" rid="ref41">41</xref>
                    </sup>
                </p>
                <fig fig-type="figure" id="f14" orientation="portrait" position="float">
                    <label>Figure 14. </label>
                    <caption>
                        <title>% Cumulative drug release of Carvedilol in its plain form and in different CAR-SCS formulations at pH 1.2 and pH 6.8 in dissolution studies.</title>
                        <p>PD: Plain Carvedilol.</p>
                    </caption>
                    <graphic id="gr14" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure14.gif"/>
                </fig>
                <fig fig-type="figure" id="f15" orientation="portrait" position="float">
                    <label>Figure 15. </label>
                    <caption>
                        <title>Comparative dissolution profiles of Carvedilol (plain CAR) and F8 formulation (optimized Carvedilol-Solid crystal suspension formulation) in different dissolution media.</title>
                        <p>(A) pH 6.8 buffer and (B) HCl solution (pH 1.2).</p>
                    </caption>
                    <graphic id="gr15" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure15.gif"/>
                </fig>
            </sec>
            <sec id="sec40">
                <title>
                    <italic toggle="yes"> Ex vivo</italic> intestinal permeation studies</title>
                <p>The permeation profile of the optimized CAR-SCS 
                    <italic toggle="yes">via</italic> the non-everted intestinal segment at different time intervals is depicted in 
                    <xref ref-type="fig" rid="f16">Figure 16</xref>. The apparent permeability coefficient (P
                    <italic toggle="yes">app</italic>) values for plain CAR and CAR-SCS (F8) formulation were found to be 0.066 cm/min and 0.122 cm/min. The P
                    <italic toggle="yes">app</italic> for optimized CAR-SCS (F8) was 1.84 folds higher than plain CAR which could be possibly due to the higher permeation of the CAR-SCS (F8) formulation 
                    <italic toggle="yes">via</italic> the intestinal membrane owing to its better solubility and dissolution rate compared to the plain CAR. Drug absorption is a result of the capacity of the drug to diffuse through the lipophilic membrane of the intestine and its solubility in the aqueous milieu. Hence, the drug must be dissolved adequately to ensure higher permeation and bioavailability.
                    <sup>
                        <xref ref-type="bibr" rid="ref44">44</xref>
                    </sup> The higher permeation of the CAR-SCS (F8) compared to the CAR could be because of the higher solubility of CAR in the melted hydrophilic carrier mannitol which helps in wetting of the CAR particles.</p>
                <fig fig-type="figure" id="f16" orientation="portrait" position="float">
                    <label>Figure 16. </label>
                    <caption>
                        <title>
                            <italic toggle="yes">Ex vivo</italic> intestinal permeation profiles of Carvedilol (plain CAR) and Carvedilol-Solid crystal suspension (F8).</title>
                        <p>Note: Data represented as mean&#x00b1; SD (n=3).</p>
                    </caption>
                    <graphic id="gr16" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure16.gif"/>
                </fig>
            </sec>
            <sec id="sec41">
                <title>
                    <italic toggle="yes"> In vivo</italic> pharmacokinetic (PK) study</title>
                <p>The 
                    <italic toggle="yes">in vivo</italic> performance of CAR-SCS (F8) was evaluated and is represented in 
                    <xref ref-type="fig" rid="f17">Figure 17</xref>. Compared to CAR alone and PM, CAR-SCS showed improved 
                    <italic toggle="yes">in vivo</italic> PK profile. 
                    <xref ref-type="fig" rid="f17">Figure 17</xref> indicates the concentration-time profile of the CAR, PM and the CAR-SCS (F8). The Cmax and tmax after administering single dose of 40 mg/kg of CAR were 2459.95 &#x00b1; 35.00 ng/mL and 0.75 &#x00b1; 0.353 h respectively. The C
                    <sub>max</sub> of PM and CAR-SCS (F8) was enhanced 1.176-fold and 3.07-fold respectively in comparison to the C
                    <sub>max</sub> of plain CAR. The difference in the tmax and Cmax values for the CAR, PM and CAR-SCS (F8) was statistically significant (
                    <italic toggle="yes">p</italic> &lt; 0.05). The t
                    <sub>1/2</sub> of CAR-SCS (F8) were higher than the plain CAR depicting that the CAR-SCS showed a prolonged residence time in the body. The AUC
                    <sub>0-24</sub> for the CAR-SCS enhanced 1.50-fold than the plain CAR, indicating a noteworthy enhancement in the oral bioavailability. The pharmacokinetic parameters are represented in 
                    <xref ref-type="table" rid="T7">Table 7</xref>. This enhanced oral bioavailability may be due to the (i) enhancement in the solubility and dissolution of the CAR in the CAR-SCS, (ii) enhanced passive diffusion of CAR 
                    <italic toggle="yes">via</italic> the intestinal membrane owing to the increased concentration gradient.</p>
                <fig fig-type="figure" id="f17" orientation="portrait" position="float">
                    <label>Figure 17. </label>
                    <caption>
                        <title>
                            <italic toggle="yes">In vivo</italic> plasma concentration of Carvedilol, Carvedilol: mannitol Physical Mixture and Carvedilol-solid crystal suspension (F8).</title>
                        <p>Note: Data represented as mean&#x00b1; SD (n=4).</p>
                    </caption>
                    <graphic id="gr17" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure17.gif"/>
                </fig>
                <table-wrap id="T7" orientation="portrait" position="float">
                    <label>Table 7. </label>
                    <caption>
                        <title>Pharmacokinetic parameters of Carvedilol, Carvedilol-mannitol PM and optimized Carvedilol-Solid crystal suspension (F8).</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th align="left" colspan="1" rowspan="1" valign="top">PK parameters</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Pure CAR suspension</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">PM</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">CAR-SCS (F8)</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">Tmax (h)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.75 &#x00b1; 0.353</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.00 &#x00b1; 0.0</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2.00 &#x00b1; 0.0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">C max (ng/mL)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2459.95 &#x00b1; 35.00</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2894.40 &#x00b1; 51.47</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">7557.4 &#x00b1; 18.52</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">AUC 
                                    <sub>0-24</sub> (h*ng/mL)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">21174.80 &#x00b1; 452.30</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">19423.07 &#x00b1; 1099.6</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">30916.21 &#x00b1; 2399.2</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">AUC 
                                    <sub>0-&#x221e;</sub> (h*ng/mL)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">18405.81 &#x00b1; 16.09</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">17628.53 &#x00b1;770.18</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">27731.98 &#x00b1; 3971.8</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">T
                                    <sub>1/2</sub> (h)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">8.945 &#x00b1; 0.500</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">7.751 &#x00b1; 0.709</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">11.52 &#x00b1; 5.88</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">K
                                    <sub>el</sub> (h
                                    <sup>-1</sup>)</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.0775 &#x00b1; 0.005</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.096 &#x00b1;0.008</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">0.069 &#x00b1; 0.035</td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
            </sec>
            <sec id="sec42">
                <title>Stability studies</title>
                <p>The stability studies were performed on the CAR-SCS (F8) formulation at accelerated stability conditions (40&#x00b0;C/75% RH) for 3 months (Thermolab stability chamber, 500 L). The DSC studies revealed the crystallinity of the CAR-SCS (F8) even after 3 months. The same DSC pattern was observed throughout the stability period (
                    <xref ref-type="fig" rid="f18">Figure 18</xref>). The drug content for the CAR-SCS (F8) after a period of 1 month, 2 months and 3 months was found to be 77.73 &#x00b1; 0.98 %, 77.70 &#x00b1; 1.00 %, and 77.50 &#x00b1; 1.00 %. The results indicated that the CAR-SCS (F8) was stable for three months with no change in its appearance and drug content.</p>
                <fig fig-type="figure" id="f18" orientation="portrait" position="float">
                    <label>Figure 18. </label>
                    <caption>
                        <title>DSC Spectra of optimized Carvedilol -solid crystal suspension (F8) at the end of 3 months of stability period.</title>
                    </caption>
                    <graphic id="gr18" orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/152488/c45cb034-15f5-4a9c-ae75-305163357a85_figure18.gif"/>
                </fig>
            </sec>
        </sec>
        <sec id="sec43" sec-type="conclusions">
            <title>Conclusions</title>
            <p>Solid crystal suspensions offer a unique way for the solubility enhancement for the poorly aqueous soluble drugs. There are no reports on the preparation of SCS by a TSP process that utilizes co-rotating twin screws with different heating zones within the barrel. The solubility of CAR is affected by the high crystal lattice energy, and the solubility of CAR was considerably enhanced with mannitol. The optimized CAR-SCS (F8), prepared by utilizing a 20:80 ratio of CAR: mannitol at the kneading zone temperatures of 120&#x00b0;C and 100 rpm screw speed, showed higher hydrophilicity and lesser hydrophobicity, which could be the possible reason for the increase in the solubility of CAR in the optimized CAR-SCS (F8). DSC studies revealed the presence of CAR in the stable crystalline form in the CAR-SCS (F8). The 
                <italic toggle="yes">in vitro</italic> dissolution studies for the optimized formulation (F8) revealed a 6.03 times enhancement in dissolution rate compared to plain CAR in pH 1.2 HCl solution and a 3.40 times enhancement in pH 6.8 buffer. The results of the permeation studies illustrated that the P
                <italic toggle="yes">app</italic> for optimized F8 formulation was higher than plain CAR. The cumulative amount of drug permeated from the plain CAR and CAR-SCS (F8) at the end of 180 min was 47.67% and 98.85% respectively. The 
                <italic toggle="yes">in vivo</italic> pharmacokinetic study indicated a 3.07-fold enhancement in the C
                <sub>max</sub> of the CAR-SCS (F8) compared to the plain CAR depicting a significant enhancement in the oral bioavailability. The present platform technology and expertise involving co-rotating TSP instrument with different heating zones used in the development of CAR-SCS could be applied to various drug candidates with poor solubility.</p>
        </sec>
    </body>
    <back>
        <sec id="sec46" sec-type="data-availability">
            <title>Data availability</title>
            <sec id="sec47">
                <title>Source data</title>
                <p>Carvedilol data is available from: (no date) National Center for Biotechnology Information. PubChem Compound Database. Available at: 
                    <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/carvedilol">https://pubchem.ncbi.nlm.nih.gov/compound/carvedilol</ext-link> (Accessed: 09 September 2023).
                    <sup>

                        <xref ref-type="bibr" rid="ref44">44</xref>
</sup>
                </p>
                <p>Mannitol data is avaialble from: (no date) National Center for Biotechnology Information. PubChem Compound Database. Available at: 
                    <ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/MANNITOL">https://pubchem.ncbi.nlm.nih.gov/compound/MANNITOL</ext-link> (Accessed: 09 September 2023).
                    <sup>

                        <xref ref-type="bibr" rid="ref45">45</xref>
</sup>
                </p>
            </sec>
            <sec id="sec48">
                <title>Underlying data</title>
                <p>FigShare. Raw data, DOI: 
                    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.23613693">https://doi.org/10.6084/m9.figshare.23613693</ext-link>.
                    <sup>

                        <xref ref-type="bibr" rid="ref46">46</xref>
</sup>
                </p>
                <p>This project contains the underlying data:
                    <list list-type="alpha-lower">
                        <list-item>
                            <label>a.</label>
                            <p>The 
                                <italic toggle="yes">in vivo</italic> pharmacokinetic data for the CAR, PM and the CAR-SCS (F8)</p>
                        </list-item>
                        <list-item>
                            <label>b.</label>
                            <p>The ANOVA data generated by the Design Expert software</p>
                        </list-item>
                        <list-item>
                            <label>c.</label>
                            <p>FTIR raw data for (i) plain CAR (ii) Mannitol (iii) PM and (iv) CAR-SCS (F8)</p>
                        </list-item>
                        <list-item>
                            <label>d.</label>
                            <p>DSC raw data for (i) plain CAR (ii) Mannitol (iii) PM and (iv) CAR-SCS (F8) and</p>
                        </list-item>
                        <list-item>
                            <label>e.</label>
                            <p>XRD raw data for (i) plain CAR (ii) Mannitol (iii) PM and (iv) CAR-SCS (F8).</p>
                        </list-item>
                    </list>
                </p>
                <p>Data is available under the terms of 
                    <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons Zero &#x201c;No rights reserved&#x201d; data waiver</ext-link> (CC0 1.0 Public domain dedication).</p>
            </sec>
            <sec id="sec49">
                <title>Reporting guidelines</title>
                <p>FigShare: Untitled Item. 
                    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.23936067">https://doi.org/10.6084/m9.figshare.23936067</ext-link>.
                    <sup>

                        <xref ref-type="bibr" rid="ref47">47</xref>
</sup>
                </p>
                <p>This project contains the following ARRIVE guideline files:
                    <list list-type="bullet">
                        <list-item>
                            <label>-</label>
                            <p>ARRIVE09.09.2023.pdf</p>
                        </list-item>
                    </list>
                </p>
            </sec>
        </sec>
        <ack>
            <title>Acknowledgments</title>
            <p>The authors sincerely thank &#x2013; (i) All India Council for Technical Education (AICTE), Government of India for providing National Doctoral Fellowship to Prerana D. Navti, (ii) Department of Science and Technology, Government of India, for the INSPIRE fellowship to Soji Soman, (iii) Board of Research in Nuclear Science (BRNS), Department of Atomic Energy, Government of India for providing a research grant (No. 54/14/06/2021-BRNS/10342) and Junior Research Fellowship to Sanjay Kulkarni and (iv) Manipal Academy of Higher Education (MAHE), Manipal for providing Dr. T.M.A Pai Doctoral Fellowship to Gasper Fernandes, Ajinkya N Nikam, and Sumit Birangal. The authors are grateful to Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal and SteerLife Bangalore for providing the facilities and support.</p>
        </ack>
        <ref-list>
            <title>References</title>
            <ref id="ref1">
                <label>1</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Kumar</surname>
                            <given-names>AMS</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kulyadi</surname>
                            <given-names>GP</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Mutalik</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Application of hot melt extrusion for the solubility enhancement of a BCS class II drug.</article-title>
                    <source>

                        <italic toggle="yes">Res. J. Pharm. Technol.</italic>
</source>
                    <year>2019</year>;<volume>12</volume>(<issue>8</issue>):<fpage>3751</fpage>&#x2013;<lpage>3754</lpage>.
                    <pub-id pub-id-type="doi">10.5958/0974-360X.2019.00642.5</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref2">
                <label>2</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Poovi</surname>
                            <given-names>G</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Damodharan</surname>
                            <given-names>N</given-names>
                        </name>
</person-group>:
                    <article-title>Lipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs.</article-title>
                    <source>

                        <italic toggle="yes">Future J. Pharm. Sci.</italic>
</source>
                    <year>2018</year>;<volume>4</volume>(<issue>2</issue>):<fpage>191</fpage>&#x2013;<lpage>205</lpage>.
                    <pub-id pub-id-type="doi">10.1016/j.fjps.2018.04.001</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref3">
                <label>3</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Fernandes</surname>
                            <given-names>GJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rathnanand</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kulkarni</surname>
                            <given-names>V</given-names>
                        </name>
</person-group>:
                    <article-title>Mechanochemical Synthesis of Carvedilol Cocrystals Utilizing Hot Melt Extrusion Technology.</article-title>
                    <source>

                        <italic toggle="yes">J. Pharm. Innov.</italic>
</source>
                    <year>2019</year>;<volume>14</volume>(<issue>4</issue>):<fpage>373</fpage>&#x2013;<lpage>381</lpage>.
                    <pub-id pub-id-type="doi">10.1007/s12247-018-9360-y</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref4">
                <label>4</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Thommes</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ely</surname>
                            <given-names>DR</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Carvajal</surname>
                            <given-names>MT</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Improvement of the Dissolution Rate of Poorly Soluble Drugs by Solid Crystal Suspensions.</article-title>
                    <source>

                        <italic toggle="yes">Mol. Pharm.</italic>
</source>
                    <year>2011</year>;<volume>8</volume>(<issue>3</issue>):<fpage>727</fpage>&#x2013;<lpage>735</lpage>.
                    <pub-id pub-id-type="pmid">21344937</pub-id>
                    <pub-id pub-id-type="doi">10.1021/mp1003493</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref5">
                <label>5</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Pawar</surname>
                            <given-names>JN</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Fule</surname>
                            <given-names>RA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Maniruzzaman</surname>
                            <given-names>M</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Solid crystal suspension of Efavirenz using hot melt extrusion: Exploring the role of crystalline polyols in improving solubility and dissolution rate.</article-title>
                    <source>

                        <italic toggle="yes">Mater. Sci. Eng. C.</italic>
</source>
                    <year>2017</year>;<volume>78</volume>:<fpage>1023</fpage>&#x2013;<lpage>1034</lpage>.
                    <pub-id pub-id-type="pmid">28575936</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.msec.2017.04.055</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref6">
                <label>6</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Reitz</surname>
                            <given-names>E</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Vervaet</surname>
                            <given-names>C</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Neubert</surname>
                            <given-names>RHH</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Solid crystal suspensions containing griseofulvin &#x2013; Preparation and bioavailability testing.</article-title>
                    <source>

                        <italic toggle="yes">Eur. J. Pharm. Biopharm.</italic>
</source>
                    <year>2013</year>;<volume>83</volume>(<issue>2</issue>):<fpage>193</fpage>&#x2013;<lpage>202</lpage>.
                    <pub-id pub-id-type="pmid">23108185</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.ejpb.2012.09.012</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref7">
                <label>7</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Fernandes</surname>
                            <given-names>GJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kumar</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sharma</surname>
                            <given-names>K</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>A Review on Solubility Enhancement of Carvedilol&#x2014;a BCS Class II Drug.</article-title>
                    <source>

                        <italic toggle="yes">J. Pharm. Innov.</italic>
</source>
                    <year>2018</year>;<volume>13</volume>(<issue>3</issue>):<fpage>197</fpage>&#x2013;<lpage>212</lpage>.
                    <pub-id pub-id-type="doi">10.1007/s12247-018-9319-z</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref8">
                <label>8</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Bhagat</surname>
                            <given-names>C</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Singh</surname>
                            <given-names>SK</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Verma</surname>
                            <given-names>PRP</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Crystalline and amorphous carvedilol-loaded nanoemulsions: formulation optimisation using response surface methodology.</article-title>
                    <source>

                        <italic toggle="yes">J. Exp. Nanosci.</italic>
</source>
                    <year>2013</year>;<volume>8</volume>(<issue>7-8</issue>):<fpage>971</fpage>&#x2013;<lpage>992</lpage>.
                    <pub-id pub-id-type="doi">10.1080/17458080.2011.630037</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref9">
                <label>9</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Potluri</surname>
                            <given-names>RHK</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bandari</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Jukanti</surname>
                            <given-names>R</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Solubility enhancement and physicochemical characterization of carvedilol solid dispersion with Gelucire 50/13.</article-title>
                    <source>

                        <italic toggle="yes">Arch. Pharm. Res.</italic>
</source>
                    <year>2011</year>;<volume>34</volume>(<issue>1</issue>):<fpage>51</fpage>&#x2013;<lpage>57</lpage>.
                    <pub-id pub-id-type="pmid">21468915</pub-id>
                    <pub-id pub-id-type="doi">10.1007/s12272-011-0106-3</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref10">
                <label>10</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Yuvaraja</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Khanam</surname>
                            <given-names>J</given-names>
                        </name>
</person-group>:
                    <article-title>Enhancement of carvedilol solubility by solid dispersion technique using cyclodextrins, water soluble polymers and hydroxyl acid.</article-title>
                    <source>

                        <italic toggle="yes">J. Pharm. Biomed. Anal.</italic>
</source>
                    <year>2014</year>;<volume>96</volume>:<fpage>10</fpage>&#x2013;<lpage>20</lpage>.
                    <pub-id pub-id-type="pmid">24705456</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.jpba.2014.03.019</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref11">
                <label>11</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Alonso</surname>
                            <given-names>ECP</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Riccomini</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Silva</surname>
                            <given-names>LAD</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Development of carvedilol-cyclodextrin inclusion complexes using fluid-bed granulation: a novel solid-state complexation alternative with technological advantages.</article-title>
                    <source>

                        <italic toggle="yes">J. Pharm. Pharmacol.</italic>
</source>
                    <year>2016</year>;<volume>68</volume>(<issue>10</issue>):<fpage>1299</fpage>&#x2013;<lpage>1309</lpage>.
                    <pub-id pub-id-type="pmid">27465985</pub-id>
                    <pub-id pub-id-type="doi">10.1111/jphp.12601</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref12">
                <label>12</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Wen</surname>
                            <given-names>X</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Tan</surname>
                            <given-names>F</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Jing</surname>
                            <given-names>Z</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Preparation and study the 1:2 inclusion complex of carvedilol with beta-cyclodextrin.</article-title>
                    <source>

                        <italic toggle="yes">J. Pharm. Biomed. Anal.</italic>
</source>
                    <year>2004</year>;<volume>34</volume>(<issue>3</issue>):<fpage>517</fpage>&#x2013;<lpage>523</lpage>.
                    <pub-id pub-id-type="pmid">15127807</pub-id>
                    <pub-id pub-id-type="doi">10.1016/s0731-7085(03)00576-4</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref13">
                <label>13</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Eesam</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bhandaru</surname>
                            <given-names>JS</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Naliganti</surname>
                            <given-names>C</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Solubility enhancement of carvedilol using drug&#x2013;drug cocrystallization with hydrochlorothiazide.</article-title>
                    <source>

                        <italic toggle="yes">Future J. Pharm. Sci.</italic>
</source>
                    <year>2020</year>;<volume>6</volume>(<issue>1</issue>):<fpage>77</fpage>.
                    <pub-id pub-id-type="doi">10.1186/s43094-020-00083-5</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref14">
                <label>14</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Shayanfar</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Jouyban</surname>
                            <given-names>A</given-names>
                        </name>
</person-group>:
                    <article-title>Drug&#x2013;Drug Coamorphous Systems: Characterization and Physicochemical Properties of Coamorphous Atorvastatin with Carvedilol and Glibenclamide.</article-title>
                    <source>

                        <italic toggle="yes">J. Pharm. Innov.</italic>
</source>
                    <year>2013</year>;<volume>8</volume>(<issue>4</issue>):<fpage>218</fpage>&#x2013;<lpage>228</lpage>.
                    <pub-id pub-id-type="doi">10.1007/s12247-013-9162-1</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref15">
                <label>15</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Manne</surname>
                            <given-names>ASN</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hegde</surname>
                            <given-names>AR</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Raut</surname>
                            <given-names>SY</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Hot liquid extrusion assisted drug-cyclodextrin complexation: a novel continuous manufacturing method for solubility and bioavailability enhancement of drugs.</article-title>
                    <source>

                        <italic toggle="yes">Drug Deliv. Transl. Res.</italic>
</source>
                    <year>2021</year>;<volume>11</volume>(<issue>3</issue>):<fpage>1273</fpage>&#x2013;<lpage>1287</lpage>.
                    <pub-id pub-id-type="pmid">32959332</pub-id>
                    <pub-id pub-id-type="doi">10.1007/s13346-020-00854-w</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8096738</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref16">
                <label>16</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Fernandes</surname>
                            <given-names>G</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pusuluri</surname>
                            <given-names>SLA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nikam</surname>
                            <given-names>AN</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Solvent Free Twin Screw Processed Silybin Nanophytophospholipid: In Silico, in vitro and in vivo Insights.</article-title>
                    <source>

                        <italic toggle="yes">Pharmaceutics.</italic>
</source>
                    <year>2022</year>;<volume>14</volume>(<issue>12</issue>):<fpage>2729</fpage>.
                    <pub-id pub-id-type="pmid">36559222</pub-id>
                    <pub-id pub-id-type="doi">10.3390/pharmaceutics14122729</pub-id>
                    <pub-id pub-id-type="pmcid">PMC9782009</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref17">
                <label>17</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Alshetaili</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Alshahrani</surname>
                            <given-names>SM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Almutairy</surname>
                            <given-names>BK</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Hot Melt Extrusion Processing Parameters Optimization.</article-title>
                    <source>

                        <italic toggle="yes">Processes.</italic>
</source>
                    <year>2020</year>;<volume>8</volume>(<issue>11</issue>):<fpage>1516</fpage>.
                    <pub-id pub-id-type="doi">10.3390/pr8111516</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref18">
                <label>18</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Chaudhari</surname>
                            <given-names>P</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Naik</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sruthi Mallela</surname>
                            <given-names>L</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>A supramolecular thermosensitive gel of ketoconazole for ocular applications: In silico, in vitro, and ex vivo studies.</article-title>
                    <source>

                        <italic toggle="yes">Int. J. Pharm.</italic>
</source>
                    <year>2022</year>;<volume>613</volume>:<fpage>121409</fpage>.
                    <pub-id pub-id-type="pmid">34952148</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.121409</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref19">
                <label>19</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Eedara</surname>
                            <given-names>BB</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nyavanandi</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Narala</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Improved Dissolution Rate and Intestinal Absorption of Fexofenadine Hydrochloride by the Preparation of Solid Dispersions: in vitro and In Situ Evaluation.</article-title>
                    <source>

                        <italic toggle="yes">Pharmaceutics.</italic>
</source>
                    <year>2021</year>;<volume>13</volume>(<issue>3</issue>):<fpage>310</fpage>.
                    <pub-id pub-id-type="doi">10.3390/pharmaceutics13030310</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref20">
                <label>20</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Khan</surname>
                            <given-names>FM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ahmad</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Idrees</surname>
                            <given-names>HA</given-names>
                        </name>
</person-group>:
                    <article-title>Simvastatin-Nicotinamide Co-Crystals: Formation, Pharmaceutical Characterization and in vivo Profile.</article-title>
                    <source>

                        <italic toggle="yes">Drug Des. Devel. Ther.</italic>
</source>
                    <year>2020</year>;<volume>14</volume>:<fpage>4303</fpage>&#x2013;<lpage>4313</lpage>.
                    <pub-id pub-id-type="pmid">33116417</pub-id>
                    <pub-id pub-id-type="doi">10.2147/DDDT.S270742</pub-id>
                    <pub-id pub-id-type="pmcid">PMC7584516</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref21">
                <label>21</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Daurio</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nagapudi</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Li</surname>
                            <given-names>L</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Application of twin screw extrusion to the manufacture of cocrystals: scale-up of AMG 517&#x2013;sorbic acid cocrystal production.</article-title>
                    <source>

                        <italic toggle="yes">Faraday Discuss.</italic>
</source>
                    <year>2014</year>;<volume>170</volume>:<fpage>235</fpage>&#x2013;<lpage>249</lpage>.
                    <pub-id pub-id-type="pmid">25406487</pub-id>
                    <pub-id pub-id-type="doi">10.1039/C3FD00153A</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref22">
                <label>22</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ahmed</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Shimpi</surname>
                            <given-names>MR</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Velaga</surname>
                            <given-names>SP</given-names>
                        </name>
</person-group>:
                    <article-title>Relationship between mechanical properties and crystal structure in cocrystals and salt of paracetamol.</article-title>
                    <source>

                        <italic toggle="yes">Drug Dev. Ind. Pharm.</italic>
</source>
                    <year>2017</year>;<volume>43</volume>(<issue>1</issue>):<fpage>89</fpage>&#x2013;<lpage>97</lpage>.
                    <pub-id pub-id-type="pmid">27486671</pub-id>
                    <pub-id pub-id-type="doi">10.1080/03639045.2016.1220568</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref23">
                <label>23</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Kumar</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Suhas</surname>
                            <given-names>B</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pai</surname>
                            <given-names>K</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Determination of Saturated Solubility of Naproxen using UV Visible Spectrophotometer.</article-title>
                    <source>

                        <italic toggle="yes">Res. J. Pharm. Technol.</italic>
</source>
                    <year>2015</year>;<volume>8</volume>:<fpage>825</fpage>.
                    <pub-id pub-id-type="doi">10.5958/0974-360X.2015.00134.1</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref24">
                <label>24</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Srinivasan</surname>
                            <given-names>P</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Almutairi</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dumpa</surname>
                            <given-names>N</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Theophylline-nicotinamide pharmaceutical co-crystals generated using hot melt extrusion technology: Impact of polymeric carriers on processability.</article-title>
                    <source>

                        <italic toggle="yes">J. Drug Deliv. Sci. Technol.</italic>
</source>
                    <year>2021</year>;<volume>61</volume>:<fpage>102128</fpage>.
                    <pub-id pub-id-type="doi">10.1016/j.jddst.2020.102128</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref25">
                <label>25</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Song</surname>
                            <given-names>IS</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nam</surname>
                            <given-names>SJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Jeon</surname>
                            <given-names>JH</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Enhanced Bioavailability and Efficacy of Silymarin Solid Dispersion in Rats with Acetaminophen-Induced Hepatotoxicity.</article-title>
                    <source>

                        <italic toggle="yes">Pharmaceutics.</italic>
</source>
                    <year>2021</year>;<volume>13</volume>(<issue>5</issue>):<fpage>628</fpage>.
                    <pub-id pub-id-type="pmid">33925040</pub-id>
                    <pub-id pub-id-type="doi">10.3390/pharmaceutics13050628</pub-id>
                    <pub-id pub-id-type="pmcid">PMC8146637</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref26">
                <label>26</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ezzat</surname>
                            <given-names>HM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Elnaggar</surname>
                            <given-names>YSR</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Abdallah</surname>
                            <given-names>OY</given-names>
                        </name>
</person-group>:
                    <article-title>Improved oral bioavailability of the anticancer drug catechin using chitosomes: Design, in-vitro appraisal and in-vivo studies.</article-title>
                    <source>

                        <italic toggle="yes">Int. J. Pharm.</italic>
</source>
                    <year>2019</year>;<volume>565</volume>:<fpage>488</fpage>&#x2013;<lpage>498</lpage>.
                    <pub-id pub-id-type="pmid">31100382</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.ijpharm.2019.05.034</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref27">
                <label>27</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Unver</surname>
                            <given-names>E</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Tosun</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Olmez</surname>
                            <given-names>H</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>The Effect of Taxifolin on Cisplatin-Induced Pulmonary Damage in Rats: A Biochemical and Histopathological Evaluation.</article-title>
                    <source>

                        <italic toggle="yes">Mediat. Inflamm.</italic>
</source>
                    <year>2019</year>;<volume>2019</volume>:<fpage>1</fpage>&#x2013;<lpage>6</lpage>.
                    <pub-id pub-id-type="pmid">30992689</pub-id>
                    <pub-id pub-id-type="doi">10.1155/2019/3740867</pub-id>
                    <pub-id pub-id-type="pmcid">PMC6434269</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref28">
                <label>28</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Bothiraja</surname>
                            <given-names>C</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pawar</surname>
                            <given-names>AP</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dama</surname>
                            <given-names>GY</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Novel solvent-free gelucire extract of Plumbago zeylanica using non-everted rat intestinal sac method for improved therapeutic efficacy of plumbagin.</article-title>
                    <source>

                        <italic toggle="yes">J. Pharmacol. Toxicol. Methods.</italic>
</source>
                    <year>2012</year>;<volume>66</volume>(<issue>1</issue>):<fpage>35</fpage>&#x2013;<lpage>42</lpage>.
                    <pub-id pub-id-type="pmid">22652081</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.vascn.2012.05.007</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref29">
                <label>29</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Macek</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kl&#x00ed;ma</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pt&#x00e1;&#x010d;ek</surname>
                            <given-names>P</given-names>
                        </name>
</person-group>:
                    <article-title>Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography.</article-title>
                    <source>

                        <italic toggle="yes">J. Chromatogr. B.</italic>
</source>
                    <year>2006</year>;<volume>832</volume>(<issue>1</issue>):<fpage>169</fpage>&#x2013;<lpage>172</lpage>.
                    <pub-id pub-id-type="pmid">16426905</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.jchromb.2005.12.035</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref30">
                <label>30</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Khodaverdi</surname>
                            <given-names>E</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Khalili</surname>
                            <given-names>N</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zangiabadi</surname>
                            <given-names>F</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Preparation, Characterization and Stability Studies of Glassy Solid Dispersions of Indomethacin using PVP and Isomalt as carriers.</article-title>
                    <source>

                        <italic toggle="yes">Iran. J. Basic Med. Sci.</italic>
</source>
                    <year>2012</year>;<volume>15</volume>(<issue>3</issue>):<fpage>820</fpage>&#x2013;<lpage>832</lpage>.
                    <pub-id pub-id-type="pmid">23493157</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref31">
                <label>31</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Gallo</surname>
                            <given-names>RC</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ferreira</surname>
                            <given-names>APG</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Castro</surname>
                            <given-names>REA</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Studying the thermal decomposition of carvedilol by coupled TG-FTIR.</article-title>
                    <source>

                        <italic toggle="yes">J. Therm. Anal. Calorim.</italic>
</source>
                    <year>2016</year>;<volume>123</volume>(<issue>3</issue>):<fpage>2307</fpage>&#x2013;<lpage>2312</lpage>.
                    <pub-id pub-id-type="doi">10.1007/s10973-015-4931-3</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref32">
                <label>32</label>
                <mixed-citation publication-type="other">
                    <article-title>Drug loading with supercritical carbon dioxide deposition on different silica derivatives: Carvedilol study - ScienceDirect.</article-title>Accessed December 21, 2022.
                    <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/science/article/abs/pii/S1773224719305519">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref33">
                <label>33</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Sadr</surname>
                            <given-names>MH</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Nabipour</surname>
                            <given-names>H</given-names>
                        </name>
</person-group>:
                    <article-title>Synthesis and identification of carvedilol nanoparticles by ultrasound method.</article-title>
                    <source>

                        <italic toggle="yes">J. Nanostructure Chem.</italic>
</source>
                    <year>2013</year>;<volume>3</volume>(<issue>1</issue>):<fpage>26</fpage>.
                    <pub-id pub-id-type="doi">10.1186/2193-8865-3-26</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref34">
                <label>34</label>
                <mixed-citation publication-type="other">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Rajbanshi</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Bajracharya</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Shreshtha</surname>
                            <given-names>AK</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Dissolution enhancement of Aceclofenac tablet by solid dispersion technique.</article-title>Accessed December 7, 2022.
                    <ext-link ext-link-type="uri" xlink:href="https://www.longdom.org/proceedings/dissolution-enhancement-of-aceclofenac-tablet-by-solid-dispersion-technique-10814.html">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref35">
                <label>35</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Vasilev</surname>
                            <given-names>NA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Surov</surname>
                            <given-names>AO</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Voronin</surname>
                            <given-names>AP</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Novel cocrystals of itraconazole: Insights from phase diagrams, formation thermodynamics and solubility.</article-title>
                    <source>

                        <italic toggle="yes">Int. J. Pharm.</italic>
</source>
                    <year>2021</year>;<volume>599</volume>:<fpage>120441</fpage>.
                    <pub-id pub-id-type="pmid">33675927</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120441</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref36">
                <label>36</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Marques</surname>
                            <given-names>MPM</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Oliveira</surname>
                            <given-names>PJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Moreno</surname>
                            <given-names>AJM</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Study of carvedilol by combined Raman spectroscopy andab initio MO calculations.</article-title>
                    <source>

                        <italic toggle="yes">J. Raman Spectrosc.</italic>
</source>
                    <year>2002</year>;<volume>33</volume>(<issue>10</issue>):<fpage>778</fpage>&#x2013;<lpage>783</lpage>.
                    <pub-id pub-id-type="doi">10.1002/jrs.916</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref37">
                <label>37</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Billes</surname>
                            <given-names>F</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pataki</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Unsalan</surname>
                            <given-names>O</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Solvent effect on the vibrational spectra of Carvedilol.</article-title>
                    <source>

                        <italic toggle="yes">Spectrochim. Acta A Mol. Biomol. Spectrosc.</italic>
</source>
                    <year>2012</year>;<volume>95</volume>:<fpage>148</fpage>&#x2013;<lpage>164</lpage>.
                    <pub-id pub-id-type="pmid">22617221</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.saa.2012.04.029</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref38">
                <label>38</label>
                <mixed-citation publication-type="other">
                    <article-title>A Calibration-Free Application of Raman Spectroscopy to the Monitoring of Mannitol Crystallization and Its Polymorphic Transformation|Organic Process Research &amp; Development.</article-title>Accessed December 7, 2022.
                    <pub-id pub-id-type="doi">10.1021/op100142k</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref39">
                <label>39</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Gadape</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Parikh</surname>
                            <given-names>K</given-names>
                        </name>
</person-group>:
                    <article-title>Quantitative determination and validation of Carvedilol in pharmaceuticals using quantitative nuclear magnetic resonance spectroscopy.</article-title>
                    <source>

                        <italic toggle="yes">Anal. Methods.</italic>
</source>
                    <year>2011</year>;<volume>3</volume>(<issue>10</issue>):<fpage>2341</fpage>&#x2013;<lpage>2347</lpage>.
                    <pub-id pub-id-type="doi">10.1039/C1AY05247K</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref40">
                <label>40</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Sari</surname>
                            <given-names>A</given-names>
                        </name>
</person-group>:
                    <article-title>Thermal energy storage properties of mannitol&#x2013;fatty acid esters as novel organic solid&#x2013;liquid phase change materials.</article-title>
                    <source>

                        <italic toggle="yes">Energy Convers. Manag.</italic>
</source>
                    <year>2012</year>;<volume>64</volume>:<fpage>68</fpage>&#x2013;<lpage>78</lpage>.
                    <pub-id pub-id-type="doi">10.1016/j.enconman.2012.07.003</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref41">
                <label>41</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Shah</surname>
                            <given-names>R</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Patel</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Patel</surname>
                            <given-names>H</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Development and validation of dissolution method for carvedilol compression-coated tablets.</article-title>
                    <source>

                        <italic toggle="yes">Braz. J. Pharm. Sci.</italic>
</source>
                    <year>2011</year>;<volume>47</volume>(<issue>4</issue>):<fpage>899</fpage>&#x2013;<lpage>906</lpage>.
                    <pub-id pub-id-type="doi">10.1590/S1984-82502011000400027</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref42">
                <label>42</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Pawar</surname>
                            <given-names>JN</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Fule</surname>
                            <given-names>RA</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Maniruzzaman</surname>
                            <given-names>M</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Solid crystal suspension of Efavirenz using hot melt extrusion: Exploring the role of crystalline polyols in improving solubility and dissolution rate.</article-title>
                    <source>

                        <italic toggle="yes">Mater. Sci. Eng. C Mater. Biol. Appl.</italic>
</source>
                    <year>2017</year>;<volume>78</volume>:<fpage>1023</fpage>&#x2013;<lpage>1034</lpage>.
                    <pub-id pub-id-type="pmid">28575936</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.msec.2017.04.055</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref43">
                <label>43</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Halder</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ogino</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Seto</surname>
                            <given-names>Y</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Improved biopharmaceutical properties of carvedilol employing 
                        <italic toggle="yes">&#x03b1;</italic>-tocopheryl polyethylene glycol 1000 succinate-based self-emulsifying drug delivery system.</article-title>
                    <source>

                        <italic toggle="yes">Drug Dev. Ind. Pharm.</italic>
</source>
                    <year>2018</year>;<volume>44</volume>(<issue>11</issue>):<fpage>1838</fpage>&#x2013;<lpage>1844</lpage>.
                    <pub-id pub-id-type="pmid">30059249</pub-id>
                    <pub-id pub-id-type="doi">10.1080/03639045.2018.1503294</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref44">
                <label>44</label>
                <mixed-citation publication-type="other">
                    <article-title>[PDF] FORMULATION, DEVELOPMENT AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLET OF METHIMAZOLE|Semantic Scholar.</article-title>Accessed December 7, 2022.
                    <ext-link ext-link-type="uri" xlink:href="https://www.semanticscholar.org/paper/FORMULATION-%2C-DEVELOPMENT-AND-EVALUATION-OF-RELEASE-Patil-Farooque/5a2698c4455c53051c761e8a224005f93ec03d4b">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref45">
                <label>45</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Alves</surname>
                            <given-names>TFR</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Barros</surname>
                            <given-names>CT</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Baldo</surname>
                            <given-names>D</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Preparation, Characterization and ex vivo Intestinal Permeability Studies of Ibuprofen Solid Dispersion.</article-title>
                    <source>

                        <italic toggle="yes">J. Dispers. Sci. Technol.</italic>
</source>
                    <year>2019</year>;<volume>40</volume>(<issue>4</issue>):<fpage>546</fpage>&#x2013;<lpage>554</lpage>.
                    <pub-id pub-id-type="doi">10.1080/01932691.2018.1472014</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref46">
                <label>46</label>
                <mixed-citation publication-type="data">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Navti</surname>
                            <given-names>PD</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Fernandes</surname>
                            <given-names>G</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Soman</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <data-title>Co-rotating twin screw process for continuous manufacturing of solid crystal suspension: A promising strategy to enhance the solubility, permeation and oral bioavailability of Carvedilol. figshare.</data-title>Dataset.<year>2023</year>.
                    <pub-id pub-id-type="doi">10.6084/m9.figshare.23613693</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref47">
                <label>47</label>
                <mixed-citation publication-type="other">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Navti</surname>
                            <given-names>PD</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Fernandes</surname>
                            <given-names>G</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Soman</surname>
                            <given-names>S</given-names>
                        </name>

                        <etal/>
</person-group>:
Co-rotating twin screw process for continuous manufacturing of solid crystal suspension: A promising strategy to enhance the solubility, permeation and oral bioavailability of Carvedilol. figshare. ARRIVE guideline files.pdf.<year>2023</year>.
                    <pub-id pub-id-type="doi">10.6084/m9.figshare.23936067</pub-id>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
    <sub-article article-type="reviewer-report" id="report227292">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.152488.r227292</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Matsunami</surname>
                        <given-names>Kensaku</given-names>
                    </name>
                    <xref ref-type="aff" rid="r227292a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-8831-018X</uri>
                </contrib>
                <aff id="r227292a1">
                    <label>1</label>Ghent University, Ghent, Belgium</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>18</day>
                <month>1</month>
                <year>2024</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2024 Matsunami K</copyright-statement>
                <copyright-year>2024</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport227292" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.139228.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve-with-reservations</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>This paper presents the application of the co-rotating twin-screw process toward the enhancement of the solubility, permeation, and oral bioavailability of Carvedilol. The authors have worked on a large variety of experimental studies (e.g., in-vivo and ex-vivo studies) as well as simulations. The paper is indeed interesting.</p>
            <p> On the other hand, the paper does not show sufficient discussion and conclusion. It seems like the authors have performed different approaches and shown all results. To be approved as a research article, the authors need to revise the discussion and the conclusion sessions to make sure "what each result means in terms of the objective of the study" and "what is the general conclusion obtained through different types of studies."</p>
            <p> </p>
            <p> While the reviewer understands the value of MD or in-silico approaches, it is not clear why in-silico approaches are necessary for your study. The introduction should be improved so that the readers can understand the necessity of MD studies.</p>
            <p> </p>
            <p> The followings are minor comments.</p>
            <p> </p>
            <p> 
                <bold>Table 1</bold>: Better to add units on the top (especially for temperature).</p>
            <p> </p>
            <p> 
                <bold>Formulation of Solid crystal suspension of Carvedilol (CAR-SCS) by TSP using BBD:&#x00a0;</bold>the authors wrote "TSP instrument parameters like kneading zone temperature, screw rpm, and formulation-related parameter (CAR: mannitol ratio)," but were there any parameters the authors assessed? If not, it is better to clarify that they are "the" parameters the authors considered.</p>
            <p> </p>
            <p> 
                <bold>Results- Statistical analysis and optimization using BBD: </bold>The results of ANOVA analysis are not clear. Normally, ANOVA results tell which main effects and interactions are statistically significant. However, no value is shown for each factor.</p>
            <p> </p>
            <p> The authors did only one trial for the validation. The reviewer wonders if it is not sufficient to validate the model and the authors do either more validation or other analysis to prove the accuracy of the model.</p>
            <p>Is the work clearly and accurately presented and does it cite the current literature?</p>
            <p>Partly</p>
            <p>If applicable, is the statistical analysis and its interpretation appropriate?</p>
            <p>Partly</p>
            <p>Are all the source data underlying the results available to ensure full reproducibility?</p>
            <p>Yes</p>
            <p>Is the study design appropriate and is the work technically sound?</p>
            <p>Yes</p>
            <p>Are the conclusions drawn adequately supported by the results?</p>
            <p>Partly</p>
            <p>Are sufficient details of methods and analysis provided to allow replication by others?</p>
            <p>Yes</p>
            <p>Reviewer Expertise:</p>
            <p>Pharmaceutical engineering, process systems engineering, experimental design, data analysis, mechanistic modeling</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.</p>
        </body>
        <sub-article article-type="response" id="comment11115-227292">
            <front-stub>
                <contrib-group>
                    <contrib contrib-type="author">
                        <name>
                            <surname>Mutalik</surname>
                            <given-names>Srinivas</given-names>
                        </name>
                        <aff>Pharmaceutics, Manipal Academy of Higher Education, Manipal, Karnataka, India</aff>
                    </contrib>
                </contrib-group>
                <author-notes>
                    <fn fn-type="conflict">
                        <p>
                            <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                    </fn>
                </author-notes>
                <pub-date pub-type="epub">
                    <day>20</day>
                    <month>2</month>
                    <year>2024</year>
                </pub-date>
            </front-stub>
            <body>
                <p>Dear Sir/ Madam,</p>
                <p> We thank you for the thoughtful review of our manuscript and constructive comments. We appreciate your valuable feedback and suggestions. We have carefully addressed your comments and made revisions. Here, is our detailed response to the comments: 
                    <list list-type="bullet">
                        <list-item>
                            <p>To be approved as a research article, the authors need to revise the discussion and the conclusion sessions to make sure "what each result means in terms of the objective of the study" and "what is the general conclusion obtained through different types of studies."</p>
                        </list-item>
                    </list> 
                    <bold>Reply:</bold> We have made changes in terms of what every result means and changes in the conclusion regarding the different studies.</p>
                <p> &#x00a0; 
                    <list list-type="bullet">
                        <list-item>
                            <p>it is not clear why in-silico approaches are necessary for your study. The introduction should be improved so that the readers can understand the necessity of MD studies.</p>
                        </list-item>
                    </list> 
                    <bold>Reply</bold>:&#x00a0; We have included 
                    <italic>in-silico</italic> molecular dynamics (MD) aspects for studying the interactions between the CAR and mannitol in different ratios of CAR: mannitol (20:80, 35:65, and 50:50) employed in the study at various kneading zone temperatures (120 &#x00b0;C, 130 &#x00b0;C, and 140 &#x00b0;C) to predict the optimal ratios for preparing CAR-SCS formulations. This information is given in Introduction section as suggested.</p>
                <p> 
                    <bold>Minor Comments</bold> 
                    <list list-type="bullet">
                        <list-item>
                            <p>
                                <bold>Table 1</bold>: Better to add units on the top (especially for temperature).</p>
                        </list-item>
                    </list> 
                    <bold>Reply</bold>- The units for the temperature (&#x00b0;C) have been added. 
                    <list list-type="bullet">
                        <list-item>
                            <p>
                                <bold>Formulation of Solid crystal suspension of Carvedilol (CAR-SCS) by TSP using BBD:&#x00a0;</bold>the authors wrote "TSP instrument parameters like kneading zone temperature, screw rpm, and formulation-related parameter (CAR: mannitol ratio)," but were there any parameters the authors assessed? If not, it is better to clarify that they are "the" parameters the authors considered.</p>
                        </list-item>
                    </list> 
                    <bold>&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0;&#x00a0; Reply-</bold>The parameters screw rpm and kneading zone temperature was selected on the basis of the preliminary trials conducted. However, we considered varying CAR:mannitol ratio as a formulation related parameter to check whether varying the mannitol concentrations could have impact on the CAR-SCS
                    <bold>. </bold>This has been mentioned in the Experimental design section. 
                    <list list-type="bullet">
                        <list-item>
                            <p>
                                <bold>Results- Statistical analysis and optimization using BBD: </bold>The results of ANOVA&#x00a0;&#x00a0; analysis are not clear. Normally, ANOVA results tell which main effects and interactions are statistically significant. However, no value has been shown for each factor.</p>
                        </list-item>
                    </list> 
                    <bold>Reply</bold>- The details of ANOVA data and the value for each factor has been included the raw data uploaded with the DOI link 
                    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.23613693">https://doi.org/10.6084/m9.figshare.23613693</ext-link>.&#x00a0; The suggested changes have been made in the manuscript. The ANOVA details have been included in the &#x2018;Statistical analysis and optimization using BBD&#x2019; section.</p>
                <p> We thank you for your valuable feedback, expertise and time in reviewing our manuscript and we believe that the revisions have improved the manuscript significantly.</p>
            </body>
        </sub-article>
    </sub-article>
</article>
